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ABSTRACT 
 
 Foodborne viruses are recognized as public health concerns worldwide and therefore 
effective strategies to control their spread are being researched. Blueberries are known for their 
health benefits and antimicrobial properties. This study aimed to (1) determine the antiviral 
effects of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) against the infectivity 
of hepatitis A virus (HAV), Aichi virus (AiV) and human norovirus surrogates (feline calicivirus 
(FCV-F9) and murine norovirus (MNV-1)) at 37ºC over 24-h using standard plaque assays; (2) 
evaluate antiviral effects in model foods (apple juice (AJ) and 2% milk) and simulated gastric 
conditions at 37
o
C; and (3) determine the mechanism of action of B-PAC by comparing activity 
of monomeric catechins, procyanidin B2, B-type PAC from blueberries (B-PAC) and A-type 
PAC from cranberries (C-PAC), effects on viral structure using transmission electron 
microscopy, and on adsorption and replication. FCV-F9, MNV-1, HAV and AiV titers were 
reduced to undetectable levels after 5 min, 3-h, 30 min and 3-h with 1, 1, 2, and 5 mg/ml B-PAC, 
respectively. BJ reduced FCV-F9, MNV-1, AiV to undetectable levels and HAV by ~2 log 
PFU/ml after 3, 6, 24 and 24-h, respectively. All tested viruses were reduced to undetectable 
levels within 15 min with B-PAC (1, 2 and 5 mg/ml) in AJ (pH 3.6). B-PAC effects decreased in 
milk, where FCV-F9, MNV-1, HAV and AiV were reduced by ~ 1 log PFU/ml with 5 mg/ml 
after 24-h. B-PAC at 5 mg/ml in simulated intestinal fluid reduced all tested viruses to 
undetectable levels within 30 min. Monomeric catechins and procyanidin B2 were less effective 
than the polymeric B-PAC. Time of addition assays indicated that B-PAC had modest effects in 
preventing viral adsorption, with no significant effect on viral replication. TEM observations 
revealed moderate effects on virus structure with either damaged viral capsid or virus binding to 
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B-PAC, possibly preventing virus attachment to host cells. Overall, this study demonstrated the 
ability of BJ and B-PAC to reduce viral titers in model food systems and under simulated gastric 
conditions, suggesting their potential as preventive and therapeutic options against foodborne 
viral illnesses. 
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Introduction 
 
 
Foodborne enteric viruses are commonly associated with non-bacterial acute gastroenteritis in 
humans and animals. The epidemiologically significant foodborne viruses include human 
noroviruses, hepatitis A virus, rotaviruses, Aichi virus, hepatitis E virus, adenoviruses, sapovirus, 
astrovirus, parvoviruses and other enteroviruses. These viruses are a growing cause of public 
health concern in the United States as well as worldwide with an increasing number of outbreaks 
reported every year. For instance, in the US among the 31 pathogens that are responsible 9.4-
million foodborne illnesses, human noroviruses alone are reported to be responsible for an 
estimated 5.5 million foodborne illnesses. Foodborne viruses can be transmitted through the 
fecal-oral route by contaminated food and water, via person-to-person, contact with 
contaminated surfaces, and aerosolization. At-risk foods associated with viral outbreaks, include 
filter-feeding shellfish, fresh produce, juices, bakery items, deli meats, and other ready-to-eat 
(RTE) foods or undercooked foods. However, some of these viruses including human 
noroviruses and Aichi virus currently do not have vaccines available for their control. Give their 
widespread prevalence in the food chain, effective natural alternatives to control their spread are 
being researched. Natural plant extracts have been used for their valuable medicinal properties 
since centuries. Extracts from plant and fruit sources are known to contain abundant secondary 
metabolites mainly phenolic compounds including but not limited to anthocyanidins, 
proanthocyanidins, catechins, epicatechin gallate and tannins. Plant extracts are being studied 
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extensively as sustainable sources of potential therapeutic options and also being screened for 
their antiviral potential. 
Blueberries and its polyphenols are known for their potential health benefits including 
anticarcinogenic, neuroprotective, cardioprotective, antibacterial, and antiviral properties. 
Blueberries contain structurally related polyphenols, including anthocyanins, flavonoids, and 
proanthocyanidins (PAC), sometimes referred to as condensed tannins (1). Human norovirus 
surrogates such as feline calicivirus (FCV-F9) and murine norovirus (MNV-1) have been studied 
for survival in commercial blueberry juice (BJ) at 4ºC, where FCV-F9 was undetectable after 24 
h from initial 5 log PFU/ml, whereas MNV-1 showed minimal reduction after 21 days at 4ºC (2). 
Therefore, blueberries and blueberry phenols could potentially be used as part of a diet to prevent 
or treat human norovirus related gastroenteritis. This study aimed to explore the antiviral effects 
of blueberry polyphenols and blueberry juice against foodborne viruses (cultivable human 
norovirus surrogates and hepatitis A virus) in vitro at 37
o
C, in model food systems, and under 
conditions mimicking digestion (simulated gastric conditions). In addition, this study also 
attempted to understand the mode of action of monomeric, dimeric and polymeric units of 
blueberry polyphenols against the tested viruses. Thus, insights on the benefits of blueberry 
polyphenols in improving gastrointestinal health by preventing or alleviating human norovirus 
and hepatitis A virus disease symptoms were obtained. 
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Chapter 1 Review of literature 
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Parts of this chapter have been submitted as chapters that have been accepted for 
publication. 
1. Joshi, S.S. and D’Souza D.H. (2014). Health Benefits of Grape Seed Extract, “GRAPES”: Production, 
Phenolic Composition, and Potential Biomedical Effects, Nova Science publishers Inc., New York. 
2. D’Souza D.H. & Joshi S.S. (2015). Foodborne viruses of human health concern. Encyclopedia of Food 
and Health. Elsevier Publications.  
 
Introduction to Foodborne Viruses 
 
Annually, in the United States, among the 31 pathogens that cause an estimated 9.4-
million foodborne illnesses, human noroviruses alone are reported to be responsible for an 
estimated 5.5 million foodborne illnesses (58%), 26% hospitalizations, and 11% deaths (3). As 
an overview about viruses, they are smaller in size (nM) and unique properties than bacterial 
pathogens, with lesser complexity. Viruses are obligate intracellular parasites that are dependent 
on a host cell to replicate and unlike bacteria cannot multiply in foods or the environment (4, 5). 
Foodborne viruses are generally environmentally stable, survive adverse conditions and are 
resistant to extreme pH conditions and enzymes of the gastrointestinal tract (4). They have low 
infectious doses, as few as 10-18 human noroviral particles can cause gastrointestinal illness (6). 
Foodborne viruses can be transmitted through the fecal-oral route by contaminated food 
and water, via person-to-person, contact with contaminated surfaces, and aerosolization (7). 
Viral contamination of foods often occurs due to poor hygiene practices of infected 
foodhandlers, where public education and enforcement of hygienic practices can help reduce 
outbreak incidence. Fecally polluted waters that flow into farmlands, can contaminate crops and 
also shellfish can accumulate viruses in their gastrointestinal tract. Contaminated fresh produce 
and shellfish when eaten raw or undercooked can cause illness. At-risk foods associated with 
viral outbreaks, include filter-feeding shellfish, fresh produce, juices, bakery items, deli meats, 
and other ready-to-eat (RTE) foods or undercooked foods. Viruses that are associated with 
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foodborne and waterborne diseases include human noroviruses (HNoV), hepatitis A virus, 
rotaviruses, hepatitis E virus, adenoviruses, sapoviruses, astroviruses, aichi virus, parvoviruses, 
and other enteroviruses (8). 
Human Noroviruses 
Human noroviruses are considered as major causes of non-bacterial gastrointestinal outbreaks 
worldwide. Human noroviruses (HNoVs) belong to Caliciviridae family that consists of five 
major genera, Norovirus, Sapovirus, Vesivirus, Lagovirus, and the recent addition of Becovirus 
or Nebovirus (9). HNoVs were first reported to be discovered in an elementary school outbreak 
in 1968 in Norwalk, Ohio, where 50% of students and teachers developed gastrointestinal illness, 
from which the name “Norwalk-like” virus was derived by Albert Kapikian in 2000. HNoV 
transmission occurs all year round, however, outbreaks peak in winter (10). ‘Winter vomiting 
disease’ is the common seasonal syndrome caused by HNoV infection, characterized by mild 
gastroenteritis and symptoms like nausea, vomiting, abdominal cramps, fever and malaise, 
though emerging virulent strains are capable are causing death in the elderly and 
immunocompromised (11). The average incubation time of HNoV is 24-48 h and the self-
limiting symptoms last from 18 to 48 h. Infected individuals can shed viruses for 72 h (and even 
longer, >week) after the first symptoms appear (12). This is an important consideration for food 
handlers/workers, who need to maintain good hygienic practices to prevent transmission upon 
return to work. In addition to outbreaks associated in food settings, HNoV outbreaks are reported 
to recur yearly on cruise-ships, in elderly care facilities, and in closed environments.  
Noroviruses are non-enveloped, small about 27 to 32 nm in size, and possess a single-
stranded positive-sense RNA enclosed in a capsid (outer shell protein), with a buoyant density of 
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1.33 to 1.41g/ml (13). HNoVs have icosahedral symmetry, with a capsid that comprises of 90 
capsomeres protruding from the shell made of 90 dimers of capsid protein. The genome is about 
7.3-7.7 kb long with three open reading frames (ORF’s) (14). ORF1 encodes for a polyprotein 
that is cleaved to produce the N-terminal protein, the enzyme nucleoside triphosphatase, a 3A-
like protein, the genome-linked viral protein (VpG), a 3C-like protease, and RNA-dependent 
RNA-polymerase (15). ORF2 encodes for the major capsid protein, viral protein, VP1; and ORF 
3 encodes for a minor viral structural protein, VP2. Based on sequence analysis, the genus 
Norovirus is further divided into five genogroups, GI, GII, GIII, GIV and GV, and genogroups 
GI, GII and GIV, specifically infect humans (16, 17). Genogroup III includes bovine enteric 
calicivirus that infects cattle, and genogroup V infects mice. These genogroups are further 
subdivided into at least 32 genetic clusters (9, 18). Among the genogroups I and II, 8 genotypes 
are currently recognized in genogroup I and 19 genotypes are recognized in genogroup II.  
HNoV GII.4 genotype during the past decades has been the predominant cause of outbreaks in 
the United States, Europe, and Oceania that were responsible for 70%–80% of all HNoV 
outbreaks (particularly in health care settings) (19). More recently, canine norovirus infecting 
dogs was discovered with strains classified into genogroups IV and VI (20).  
HNoV binds to the histoblood group antigens in human intestinal epithelial cells, where 
the site of replication is considered as the upper intestinal tract (21). Genetic determinants for 
these blood group antigens play a role in susceptibility of an individual to HNoV infection. 
Human volunteer studies have shown that H type I antigen likely serves as the receptor for 
HNoV, encoded by the fucosyltransferase (fut2) gene (22). Individuals that are recessive for this 
gene, lack the Type I antigen, and are inherently resistant to HNoV infections (22).  
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HNoV GI and HNoV GII can survive in the environment and were detected after 1-week 
storage on inoculated coupons at ambient temperature using RT-PCR (23). HNoVs are known to 
survive low pH of 2.7, can retain infectivity after 60°C for 30 min and also after exposure to 20% 
ether at 4°C for 18 h (13). Their resistance to inactivation is found to be higher in foods where 
steaming of mussels did not cause any significant reduction in HNoV titers (24). HNoVs were 
also found to be resistant to chlorine inactivation with a free residual chlorine of 0.5 to 1.0 
mg/mL
 
(25). 
           The inability to cultivate HNoVs in the laboratory has hindered the development of 
vaccines and effective control measures. There is no vaccine available to date for HNoV 
prevention. Cultivable surrogates such as feline calicivirus (FCV-F9) and murine norovirus 
(MNV-1) have been extensively used to understand antigenicity of HNoVs and evaluate methods 
of inactivation. Recently, Tulane Virus and porcine enteric Sapovirus have also been considered 
as alternate surrogates. FCV-F9 of the Caliciviridae family, is a small rounded, non-enveloped, 
single-stranded RNA virus with a 7.7 kb genome, has 3 ORFs, and is transmitted through air via 
fomites (26). However, since it is transmitted via a respiratory route, it may not completely 
mimic the survival of HNoV in the environment. In addition, unlike HNoVs, FCV-F9 is sensitive 
to low pH of 2.0 to 4.0 and pH 10.0 (27).  
MNV-1 is currently the only known norovirus that replicates in the laboratory in murine 
macrophage RAW 264.7 cells (28). MNV-1 belongs to genogroup V norovirus, sharing sequence 
similarity to genogroup II that mainly infect humans (29, 30). MNV-1 is similar to HNoVs in 
immunological, biochemical, genetic and molecular properties, as MNV-1 is an icosahedral, 
non-enveloped, single-stranded RNA virus with 3 ORFs, 28-35 nm in diameter (28). Although it 
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causes a different disease in mice, it is transmitted via the fecal oral route similar to HNoVs (27). 
Unlike FCV-F9, it is less sensitive to pH within ranges of 2.0 to 10.0, however the thermal 
inactivation parameters processes like pasteurization at 63
o
C were reported to be similar for both 
FCV-F9 and MNV-1 (27). D-values required for heat inactivation of FCV-F9at temperatures of 
50, 65 and 72
o
C were reported to be 19.95 ± 0.70, 0.72 ± 0.01 and 0.21 ± 0.01 min respectively. 
For MNV-1 the reported D-values at 50, 65 and 72
o
C at were 36.28±3.21, 0.77±0.03 and 
0.25±0.01 min, respectively (31). 
Regarding application of surrogates for inactivation studies, both 200mg/ml sodium hypochlorite 
and 2% trisodium phosphate could reduce MNV-1 by 2-3 log PFU/ml and FCV-F9 to 
undetectable levels, respectively after 30 s at room temperature(32). Ozone at 6.25 ppm caused 
a~2-log Tissue culture infectious dose (TCID50/ml) reduction of FCV after 5 min and 2 log 
TCID50ml
-1
 reduction of MNV-1 after 3 min on lettuce and green onions (33). Hydrogen 
peroxide vapors (30% w/w) were found to cause 4 log reduction of FCV-F9 after 20 min on 
stainless steel, ceramic tiles, and PVC surfaces (34). MNV-1 at 7 log PFU was completely 
inactivated at a pressure of 450MPa after 5 min at 20
o
C, while 250 MPa at 20
o
C for 5 min 
reduced FCV titers by 5.1 log PFU/ml(35, 36). 
Recently, Tulane virus (TV) representing a new genus Recovirus of the Caliciviridae 
family was isolated from the stool samples of a captive juvenile rhesus macaques 
(Macacamulatta) at the Tulane National Primate Research Center. TV is 36 nm in diameter, 
icosahedral in symmetry (37). TV has the shortest known genome of around 6.7 kb among the 
known caliciviruses, contains 3 ORFS and lacks the poly (A) tail. Pairwise homology and 
phylogenetic analysis of non-structural proteins of TV revealed highest identity with HNoVs.  
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TV can be readily grown in vitro in LLC MK2 (rhesus macaque kidney) cells. TV can 
bind to histoblood group antigens like HNoVs, suggesting that the antigenic determinants and 
structural properties might be comparable to HNoVs (30). Studies have shown no significant 
differences in heat inactivation parameters between MNV-1 and TV, though MNV-1 was found 
to be more pH stable and tolerant to chlorine, while significant reduction in TV titers were 
obtained at pH 2.0 and 9.0 and after 2 ppm chlorine treatments (30, 38). Therefore, the choice of 
appropriate cultivable surrogates for HNoVs is still debatable.  
Porcine sapovirus (Cowden strain), an enteropathogen that causes gastroenteritis in 
gnotobiotic pigs is as another HNoV surrogate that can be cultivated in the swine kidney cell 
line, LLC-PK (39). Both porcine SaV and HNoV showed similar resistance to treatments at 
56oC for 30 min and 2 h and with 2.5mg/Lor 10mg/L sodium hypochlorite for 1 min; similar to 
HNoV’s, porcine SaV is stable at pH 3.0 to 8.0 (39). All these findings strongly support the use 
of porcine SaV as a surrogate to study HNoV.  
Virus like particles (VLPs): Along with the use of above viruses as HNoV surrogates, 
virus like particles (VLPs) have also been used to understand and study HNoV replication in 
vivo or to develop vaccines (40). These virus-like particles (VLPs) are non-infectious (they lack 
the genome) of HNoVs and were first expressed in baculovirus-infected insect cells (41). The 
VLP’s produced mimic the antigenic structure of the virus and also are acid and heat stable. 
These VLP’s are also highly immunogenic and produce an immune response when delivered 
intranasal, making them an ideal candidate for use in developing vaccines (42). VLPs were also 
shown to bind to carbohydrate histo-blood group antigen (HBGA) displayed on mucosal cell 
surfaces similar to human norovirus (43).  
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 Currently, there is no specific anti-viral treatment against HNoVs. Gastroenteritis and 
dehydration can be treated by oral or intravenous fluid therapy. To date, there is no vaccine 
available against HNoVs, the major barrier being the inability to culture them in vitro. Human 
volunteers re-infected with HNoV after exposure were found to be susceptible to the same strain 
as well as heterologous strains (44, 45). The spread and contamination can be prevented by 
proper sanitation and hygienic food handling practices or by heat, chemicals, or processing 
conditions described above (CDC, 2013). 
 
Hepatitis A virus  
Hepatitis A virus (HAV) belongs to the Picornaviridae family and is a positive-sense single-
stranded non-enveloped RNA virus ranging in size from 27-32 nm, similar to HNoVs. The 
genome is 7.5 kb in length and unlike HNoVs consists of a single open reading frame. The P1 
region of the genome encodes for three major viral capsid proteins VP1, VP2, and VP3. P2 and 
P3 regions encode for nonstructural proteins required for RNA replication and virion formation 
(46, 47). Only one serotype of HAV has been identified to date and a single exposure can render 
life-long immunity in an individual (48). However, genetic diversity in the strains worldwide led 
to their classification into seven genotypes designated I to VI. Genotypes I to IV are associated 
with human illnesses and genotypes V to VI include strains are obtained from affected simians 
(49).  
The largest foodborne viral outbreak associated with 292,301 cases of HAV was attributed to 
eating raw clams in Shanghai, China in 1988 (50). The most recent HAV outbreak was linked to 
the frozen antioxidant mix that contained pomegranate seeds imported from Turkey (51). About 
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165 people were confirmed to be ill following the consumption of this mix and the genotype 1B 
was implicated where it was reportedly detected in 117 stool samples of the infected persons 
(51). Several other outbreaks have been linked to sundried tomatoes and green onions (52-54). 
Given the amount of imports from different regions of the world and increasing international 
travel there has been a rise in the number of HAV cases seen every year (55). 
The average incubation period is long (unlike the short incubation period of HNoVs), 
approximately 28 days with severe symptoms that include jaundice, dark urine, vomiting, fever 
and weight loss that can last for 4 to 6 weeks. Among older children and adults, infection is 
usually symptomatic for 2 months, with jaundice occurring in 70% of patients. There are 4 
phases of HAV infection: the asymptomatic incubation phase lasts for 10 to 50 days; prodromal 
or preicteric (56, 57) phase lasts for several days to week, characterized by fatigue, nausea, and 
loss of appetite, fever, dark urine, diarrhea and pale stools; the icteric phase where jaundice 
develops along with increase in liver enzymes (namely serum transaminase and alkaline 
phosphatase) and rise bilirubin levels in blood resulting in yellowing of urine and leading to 
jaundice, and in the 4
th
 phase (convalescent) symptoms start resolving with relapse that can occur 
in 3-20% of the cases  (58).   
There are few strains of HAV (HM-175, HAS-15, MBB 11/5) that are cell-culture 
adaptable and maintained using fetal rhesus monkey kidney (FRhK-4) and/or human fetal lung 
fibroblast (MRC-5) cells. These strains produce cytopathic effects causing cell death by inducing 
apoptosis (59, 60), and used in research for inactivation studies. 
HAV is highly stable in the environment and retains infectivity in mineral water stored at 
room temperature even after 300 days (61). HAV remains infectious after a month at ambient 
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temperatures on environmental surfaces like stainless steel (62). HAV survives for >4 h on hands 
after experimental exposure (63) and during prolonged storage of spinach leaves at 5.4°C, with a 
D-value of 28.6 days (64). Sixty-two percent of inoculated HAV survived on romaine lettuce 
leaves that were stored for 12 days in a sealed-atmosphere plastic package at 4°C (65).  
         HAV survives in acid marinade at pH 3.75 over 4 weeks (66), and can retain its infectivity 
at pH 1.0 even after 5 h (67). HAV infectivity can be retained after 60 min at 60°C, being 
partially inactivated after 10-12 h at 56°C and can be inactivated in shellfish after heating at 
85°C to 90°C for 1.5 min (67, 68), and reduced to undetectable levels from 7 log PFU/ml at 
450MPa hydrostatic pressure for 5 min (69). These survival features play a significant role in the 
transmission of HAV. Once a person is infected with HAV, there are no specific treatment 
options available. However, symptoms of HAV infection may be alleviated by appropriate 
patient care that includes adequate hydration, nutrition, rest, and anti-emetics (70). For 
prevention, immunoglobulin (Ig) therapy is effective when administered within two weeks of 
viral exposure (through passive immunity). As preventive measures, inactivated and heat-killed 
vaccines against HAV are commercially available, that provide immunity against HAV for >20 
years or lifetime (71). The U.S. Centers for Disease Control and Prevention (CDC) recommend 
routine vaccination against HAV for children aged between 12 to 23 months (55). When 
economically feasible, vaccination of food-handlers is recommended to prevent HAV 
transmission and to prevent outbreaks. 
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Aichi virus  
Aichi virus (AiV) of the genus Kobuvirus in the Picornaviridae family was first isolated in 1989 
from patient stool samples in a gastrointestinal outbreak involving oysters in Aichi, Japan (72). It 
has a positive-sense single-stranded RNA and a poly (A) tail, with a single ORF encoding for 
structural proteins VP0, VP1 and VP3, and non-structural proteins 2A, 2B, 2C, 3A, 3B, 3C, 3D 
(73). AiV’s are classified into three distinct genotypes A to C (74). AiV virions are icosahedral, 
30 nm in diameter with three capsid proteins (73). AiV-related gastrointestinal cases have been 
reported from Asian, African, European and South American countries indicating its 
geographical spread and prevalence (75-80). AiV has been known to survive (without reduction) 
high pressure processing (HPP) treatment of 600 MPa for 5 min in minimum essential growth 
medium (MEM) with 10% fetal bovine serum (81). However, AiV was reduced by 1.87, 2.49 
and 4.59 log TCID50mlrespectively when treated by 240 mW s
-2
 of ultraviolet light treatment, 
that can be used to reduce AiV on fresh produce like strawberries, green onions and lettuce (82). 
AiV isolates were stable in 10% chloroform and MEM (pH 3.5) for 3h and survives heating at 
50
o
C and 60
o
C for 30 min (72). 
Hepatitis E virus  
Hepatitis E virus (HEV) is a small non-enveloped RNA virus, 32-34 nm, primarily transmitted 
through the fecal-oral route usually through contaminated water (83, 84). This virus is mainly 
predominant in developing countries in Asia and Africa (85). HEV of the genus Hepevirus in the 
Herpeviridae family, comprises of a 7.2 kb single-stranded positive-sense RNA with three open 
reading frames (ORFs) (86). The average incubation period for HEV infection is between 2 to 10 
weeks, with two distinct phases of illness. The pre-icteric phase is characterized by fever, 
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anorexia, vomiting and abdominal pain, while the icteric phase is characterized by jaundice and 
is self-limiting. Viral shedding begins 1-2 weeks before and 2-4 after onset of symptoms. A 
significant rise in serum alanine aminotransferase and aspartate aminotransferase occur, that is 
used as detection methods of liver injury (87). Due to its long incubation period, association of 
HEV with particular foods has not been established, however recent studies suggest HEV 
transmission is linked to consumption of uncooked pork meat (88). There is no specific treatment 
except patient care as described above for HAV symptom alleviation. Pegylated interferon 
administration has been tried in chronic infections with moderate success (89). Vaccine trials 
have been under study to determine preventive measures.  
 
Rotavirus  
Rotavirus (RV) of the Reoviridae family has a multilayered non-enveloped icosahedral capsid, 
ranging from 60-100 nm in size and is easily distinguishable from HNoVs or HAV by electron 
microscopy. RV has 11 segments of double-stranded RNA that code for structural proteins (VP1 
to VP8) and non-structural proteins. Rotavirus (RV) is a common cause of acute gastroenteritis 
in children younger than 5 years (90). RV was first discovered in 1973 with electron micrographs 
of intestinal and stool biopsies of children suffering from gastroenteritis, with a typical wheel 
shape and hence the Latin name “Rota” meaning wheel (91). The incubation period for human 
RV is around 1 to 3 days. Symptoms occur 48 h after RV infection that include watery diarrhea, 
abdominal pain, vomiting, and dehydration, with severe diarrhea resulting in high mortality rates 
around the world (92). In 1980’s, there were 870,000 deaths linked to RV infection globally, 
with current numbers around 450,000/year, and developing countries like the Democratic 
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Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan accounted for > half of total 
rotavirus related deaths, with India accounting for 22%  (98,621) of deaths (93, 94). Many RV 
outbreaks are known to occur due to contaminated water and unhygienic and unsanitary 
conditions (95, 96).  
Human RV can survive and retain antigenicity after 5 mgml
-1
 chlorine treatment for 60 
min (97), and is resistant to wipes containing 1000 ppm chlorine on stainless steel surfaces (98). 
High pressure processing at 350 MPa at 4
o
C caused a 1.1 log PFU reduction in RV titers (99). 
RV subjected to wet (100
o
C) and dry (60
o
C) heat for varying periods of 1-20 min led to changes 
in virion morphology and loss of smooth capsid layer (100). Commercial cranberry and grape 
juices at native pH could reduce RV infectivity after 5 min at 23
o
C (101). Other natural 
substances such as persimmon extract and wattle extract (0.5% solution) reduced human RV 
strain Wa titers by 5.3 log PFUml
-1
 after 3 min at room temperature (102). 
Animal model-systems have been developed to study and improve strategies for 
protection against infection from various RV serotypes/isolates. Two Simian RV strains SA11 
and Rhesus Rotavirus (RRV) are being used as reference strains worldwide and some of the 
currently available reassortment vaccines are based on the RRV strain(103, 104). As a preventive 
measure against human RV infection, the World Health Organization (WHO) recommends 
vaccination that has significantly reduced rotavirus-related gastroenteritis and mortality (105). 
Sapovirus  
Sapovirus of the Caliciviridiae family is a positive-sense single-stranded 7.5 kb RNA virus, 41-
46 nM in diameter, that infects humans and pigs (106). Sapporo virus (SaV), the human 
prototype was first identified in an infant home outbreak in Sapporo, Japan in 1977. It has 10 
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spikes on the outer surface. SaV is divided into five genogroups, GI to GV; Genogroups GI, GII, 
GIV and GV infect humans and GIII infects pigs. Genomes of GI, GIV, and GV contain three 
open reading frames (ORF’s) and GII genomes contain two ORFs (107, 108). RNA-dependent 
RNA polymerase and a major capsid protein (VP1) are encoded by ORF1, ORF2 encodes a 
small protein similar to VP2 of NoVs and ORF3 encodes for a protein with unknown function 
(39). Outbreaks of SaV are less frequent than HNoV, however significant increase in SaV 
outbreaks has occurred in various settings such as elementary schools, high schools, hospitals 
and hotels (109). SaV is associated with treated and untreated sewage, and river water (110). The 
average incubation time is ~24-48h with symptoms like diarrhea, abdominal pain, nausea, 
vomiting, chills, malaise and fever (111). Human SaVs like HNoVs are uncultivable (112, 113). 
As mentioned above, porcine sapovirus that is cultivable in the lab is also studied as a surrogate 
for HNoVs (39).  
Adenovirus 
Adenoviruses (AdV) were first isolated from civilians and Army recruits who had respiratory 
disease (114, 115). AdVs of the genus Mastadenovirus, are 90-100 nm, non-enveloped, contain 
26-45 kb double-stranded DNA enclosed in an icosahedral shell. Clinical manifestations of 
HAdVs range from upper and lower respiratory tract infections, pneumonia, to gastroenteritis 
and urinary tract infections (116, 117). HAdVs cause mild and self-limiting disease, and severe 
clinical presentations if any include cystits, enteritis, encephalitis and pneumonia (118). HAdV 
serotypes 40 and 41 are the second leading cause of viral gastroenteritis in children after 
rotavirus (119). Symptoms like diarrhea, dehydration, vomiting, and fever develop after an 
incubation period of 8-10 days and last for 7-8 day, with shedding for 7-14 days after infection 
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(120). 
Other enteric viruses 
Astroviruses are small, ~30 nm in size, star-shaped, non-enveloped RNA viruses, that 
were first identified in 1975 in children suffering from diarrhea in a maternity ward in England 
(121). Their name originates from the Greek word ‘astron’ meaning star, which represents the 
five star-like projections on the virus (122). Astroviruses belong to the family Astroviridae that is 
divided into two genera; Mamastroviridae (that infect mammals) and Avastroviridae (that infect 
avians) (123). Their genome is about 6.8 to 7.9 kb with a 5’ untranslated region and 3 ORFs, 
ORF1a, ORF1b and ORF2. ORF1 encodes a RNA dependent RNA polymerase and a protease 
while ORF2 encodes for the viral capsid (124). Astroviruses are not easily cultivable in vitro, 
hence the serological classification is mostly established on nucleotide and amino acid variability 
of ORF2 (124). Till date, there are eight known serotypes of human astroviruses (HAstV), with 
type 1 being the most prevalent (125-127). Along with the genetic diversity of ORF2, HAstV are 
further classified into genogroups A and B; genogroup A includes serotypes 1 to 5 and 8, 
genogroup B includes serotypes 6 and 7 (128). When culturable, the virus is grown using the 
human colon carcinoma  (Caco-2) cell line (129).  
HAstVs are reported to be a common cause of gastroenteritis in children (130). 
Symptoms related to HAstV develop 2-3 days after infection and include diarrhea, vomiting, 
abdominal pain, headache and dehydration. However, affected persons may not require 
hospitalization since the symptoms are self-resolving (120, 131). HAstV is known to infect the 
immunocompromised, elderly, and healthy adults, though children under the age of two are most 
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prone to infection (124, 132). Astrovirus is known to survive in water and surfaces for 60 days at 
4
o
C and in water at 20
o
C and after 2 h in 1mg/L free chlorine (133). 
Parvovirus of the Parvoviridae family is a small, 18-26 nM, non-enveloped single-
stranded 5kb DNA virus, discovered in 1974 while testing for hepatitis B surface antigen (134, 
135). It is icosahedral with a buoyant density of 1.39 to 1.42 g/ml. Parvovirinae are divided into 
three genera based on transcription maps, their terminal repeats and replication; Parvovirus, 
(autonomous), replication with helper virus Dependovirus and in erythrocytes Erythrovirus, and 
only Dependovirus and Erythrovirus are known to infect humans(136, 137). Parvovirus genome 
has 2 ORFs, transcribing viral proteins VP1 and VP2 and non-structural proteins, with VP2 the 
major structural protein comprising of 96% of total capsid protein (138).   
Parvoviruses are resistant to pH between 3 and 9 and at 56
o
C for 60 min, but can be 
inactivated by formalin and gamma-radiation (139). Parvoviruses have been linked to shellfish 
and the “cockle agent” parvovirus was associated with a large outbreak related with 
contaminated cockles in the UK involving around 800 people (137, 140). 
 With this information on the foodborne viruses and their transmission along with the lack 
of available vaccines in most cases, novel methods to control their spread are being researched. 
Ideally, methods should be cost-effective, easy-to-use, sustainable and natural with consumer 
appeal. Natural plant extracts and in particular plant polyphenols can serve as attractive alternate 
therapeutic or preventive options in the absence of vaccines and effective control measures. 
Natural plant extracts 
 
As indicated above, in the current absence of vaccines or effective treatment options for HNoV 
infections, natural alternatives are being evaluated (141). Plant derived polyphenols and their 
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associated health benefits as antimicrobials against bacteria are well established (142-145). In 
addition, there is an increasing demand from the consumers and the industry for natural 
alternates to synthetic chemical additives used in food systems. Extensive research on potential 
plant polyphenolic extracts, as natural antimicrobials are ongoing. Below are some of the widely 
used and studied natural plant extracts for their antimicrobial (and if known antiviral properties) 
and other health beneficial properties. 
 
Blueberry polyphenols 
Blueberries (genus Vaccinium) are perennial flowering plants native to North America. 
Blueberries are a rich source of polyphenols including anthocyanins, flavonoids and 
proanthocyanidins (PAC), also referred to as condensed tannins (1). Tannins (condensed and 
hydrolysable) differ from other phenolic compounds for they are able to precipitate proteins, 
known as astringency (146). Proanthocyanidins (PAC’s) are dimers, oligomers, and polymers of 
catechins bound together by links between C4 and C8 (or C6) where the monomeric flavanols 
differ in the stereochemistry of C-3 and their hydroxylation pattern in ring A and B (147). 
Blueberries have been known to contain around 88-261 mg of proanthocyanidin/100 gram of 
edible portion as per the USDA, 2004 database for flavonoid content. Being a source of natural 
anthocyanin and proanthocyanidins, blueberries are known to have a broad spectrum of 
biomedical benefits such as treatment/prevention of cardiovascular disorders, advancing age-
induced oxidative stress, inflammatory responses, and diverse degenerative diseases along with 
anticarcinogenic, neuroprotective, cardioprotective and antimicrobial properties (148). 
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Antibacterial properties:  Berry ellagitannins are known to possess strong antimicrobial 
properties including prevention of adherence and colonization of bacteria (149). Blueberries 
contain polyphenols including anthocyanins and flavonoids and proanthocyanidins (PAC), also 
referred to as condensed tannins (1) are known to have antimicrobial activity against Listeria 
monocytogenes, Helicobacter pylori, Salmonella Typhimurium, Escherichia coli and Candida 
albicans (143, 150, 151). Salmonella Enteritidis and Listeria monocytogenes. S. Enteritidis was 
shown to be reduced by 5.85 log CFU/ml after 24 h and L. monocytogenes by 7.64 log CFU/ml 
after 24 h by 24 ppm of blueberry water extracts. Similar reduction of 5.50 log CFU/ml and 6.52 
log CFU/ml was observed for S. Enteritidis and L. monocytogenes with blueberry ethanol extract 
after 24h (152). This data suggests that blueberry extracts can be used as antimicrobial agents in 
various food products as additives or consumed for treating infections arising from both Listeria 
and Salmonella species (152). Blueberry and cranberry contain two compounds (fructose and a 
high molecular weight polymeric compound) that inhibit adhesin, (required for the bacteria to 
adhere) thereby preventing attachment of pathogenic Escherichia coli to mucosal cells of the 
urinary bladder (151). Blueberry fractions that had concentrations of 8.9 g/L GAE for total 
blueberry extract, 8.0 g/L GAE for monomeric phenolics, 173.08 mg/L C3G for anthocyanins 
and proanthocyanidins, 139.8 mg/L C3G for anthocyanins, and 1.0 mM PA2 for 
proanthocyanidins was shown to cause 8 log CFU/ml reduction in growth of L. monocytogenes 
for all tested concentrations ranging from 0-4.45 g/L (gallic acid) and 0-86.54 g/L (cyaniding-3-
glucoside) while E. coli O157:H7 demonstrated an 8-log CFU/ml reduction in growth for all 
fractions at their highest concentrations (143). S. Typhimurium demonstrated similar log 
reductions in growth to E. coli O157:H7, except for being more susceptible to monomeric 
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phenolics and anthocyanins and less susceptible to proanthocyanidins (143). Significant 
inhibition of about 50% of Helicobacter pylori (causative agent of ulcers) was demonstrated with 
elderberry (30%), bilberry (50%), blueberry (50.5%) and OptiBerry (62%) extracts. Addition of 
clarithromycin to the 0.25% berry concentrations, led to a significant increase (about 70%) in the 
bactericidal effects of the elderberry, bilberry, blueberry and OptiBerry extracts compared with 
the berry extracts alone. Addition of 1% clarithromycin led to more than 90% of inhibition of H. 
pylori for all berry extracts (150). Another study with blueberry extracts at 25-50% w/w in 
combination with an antibiotic such as trimethoprim at about 0.001% to 10% was found to 
enhance its antimicrobial activity against attachment and subsequent biofilm formation of 
urinary tract infections causing organisms E. coli and C. albicans (153). Mechanism of 
antibacterial action: The outer bacterial membrane of bacteria provides the fundamental barrier 
against any damage. Blueberry phenolics are known to have profound effects on membrane 
fluidity, inhibition of extracellular microbial enzymes, changing the fatty acid profile, and 
disrupting metabolism disruption (154). Proanthocyanidins from blueberry (0.15 g/L Gallic acid 
equivalent), were shown to increase membrane permeability in E. coli O157:H7 (155). 
Antiviral properties: Only a few studies are reported in literature on the effects of blueberry 
extracts against viruses. The methanol extract fraction of blueberry leaves (proanthocyanidin 
more specifically epicatechin) was shown to inhibit hepatitis C virus (HCV) subgenome 
expression by binding to nuclear ribonucleoprotein A2/B1 that plays an indispensable role for 
HCV subgenome expression in replicon cells (156). The purified proanthocyanidin from 
blueberry leaf extracts was also found to suppress the expression of NS-3 (non-structural gene-3) 
protein gene in HCV (156). Similarly hydrolysable and galloylated tannins (0.03-0.1 
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microgram/ml) were shown to inhibit herpes simplex virus adsorption to its host, African green 
monkey kidney cells and human adenocarcinoma cells (157). Another study evaluated the 
influence of blueberry juice on the survival of human NoV surrogates (FCV-F9, MNV-1, and 
MS2) at refrigeration temperatures over 21 days, where FCV-F9 was shown to be completely 
reduced in BJ at 4°C after 1 day. MNV-1 showed minimal reduction on 14 days, and MS-2 
complete reduction after 7 days (2).  
Antigiardial properties: Trophozoites of Giardia duodenalis, a human intestinal parasite, were 
inhibited by blueberry polyphenols and other berry fruits like strawberry, blackberry, cloudberry 
at 166µg gallic acid equivalents. Incubation of G. duodenalis trophozoites in extracts of 
blueberries were also shown to cause their distortion, swelling, blebbing, flagellar truncation and 
increased killing, and increased the rate of spontaneous excystation of C. parvum oocysts (158). 
Antioxidant properties: In blueberries, primarily anthocyanins along with hydroxycinnamates 
such as chlorogenic acid contribute to antioxidant properties (149). Studies have shown that 
blueberries help maintain healthy blood flow via several mechanisms including healthy low-
density lipoprotein (LDL) oxidation, normal platelet aggregation, and maintenance of endothelial 
function (1, 159, 160). Fresh mature fruits of rabbiteye blueberry when assayed for their 
antioxidant properties were found to have the strongest antioxidant capacity, and the highest TPC 
(Total phenolic content; 9.44 mg gallic acid/g DW), TFC (Total flavonoid content; 36.08 mg 
rutin/g DW), and TAC (Total anthocyanin content; 24.38 mg catechin/g DW) values among 
other berries like blackberry and strawberry (1). These antioxidant properties are considered to 
be associated with phenolic acids, catechins (flavanols), and proanthocyanidins (condensed 
tannins) (1). In one study, a drink made form wild blue berries (containing approximately 375 
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mg of anthocyanins) was tested for its antioxidant potential in human volunteers for reducing 
oxidative stress and inflammation. After 6 weeks of consumption, significant reduction in levels 
of oxidized DNA was reported (161). Thus, blueberry juice consumption could be beneficial in 
relieving oxidative stress caused during chronic liver diseases.  
 
 
Anti-diabetic: With increased incidences of diabetes worldwide, there is a need to search for 
alternatives to complement the currently available therapies.  Blueberries with a wide range of 
health benefits and high amount of polyphenols are good candidates to screen for antidiabetic 
properties. Diabetes control approaches include reducing hyperglycemia through inhibition of 
carbohydrate hydrolyzing enzymes such as α -glucosidase. A study showed that phenolics from 
blueberry flowers had strong α -glucosidase inhibitory activity (162). Another study showed 
similar findings where anthocyanins and proanthocyanidins from fermented blueberry blackberry 
beverages were found to be inhibitors of carbohydrate-utilizing enzymes and inhibitors of 
inflammation (163). These studies show that consuming blueberries or their fermented beverages 
might be beneficial towards control of diabetes and inflammation. Blueberries have been shown 
to control diabetes by improving insulin sensitivity. When a cobiotic of inulin and sugar free 
blueberry pomace extract and oat was administered to a Type II diabetic patient for 8 weeks 
along with metformin (initial treatment for Type II diabetes), the blood sugar was shown to 
lower to 100mg/dL and weight loss of 5.5kg was reported. Such studies could lead into use of 
supplements from natural sources with anti diabetic properties to escalate the effect of commonly 
used drugs and reduce side effects (164). 
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Anticarcinogenic Effects: Cancer is a leading cause of death and accounted for 7.6 million 
deaths (around 13% of all deaths) in 2008. Polyphenols have been reported to have effects of on 
cancer cells by affecting growth, differentiation and apoptosis (165). Some of the studies below 
have attempted to investigate the anticancer properties associated with blueberries and its 
consumption. When blueberry anthocyanin extracts were tested for anticancer potential against 
two breast cancer cell lines (MDA-MB-231 and MCF7) at 250 μg/ml was found to have a 
significant effect (65%) in reducing cell proliferation after 24 h of cell incubation (166). 
Anticarcinogenic effects of blueberry phenolics against breast cancer were recently demonstrated 
in a study (167), where rats on 5% blueberry diet (containing 38 mg/g of total phenolics and 21 
mg/g of total anthocyanins) in chemopreventive and therapeutic modes were shown to have 
delayed tumor development by 28 and 35 days respectively to 17β-estradiol induced breast 
cancer. Additionally, 96% animals in a control group were shown to develop palpable mammary 
tumors compared to 60% and 55% animals in chemopreventive and therapeutic groups 
respectively (167). The study suggests anticancer and protective role of blueberries by regulating 
tumor development. 
Cardioprotective effects: Cardio protective effects of blueberry extracts and its components are 
being extensively studied. Effects of blueberry supplementation in diets on metabolic syndrome, 
lipid peroxidation and inflammation were evaluated in obese men and women (168). After 8 
weeks of dietary blueberry supplementation (50 g freeze-dried blueberries; 350 g fresh 
blueberries), a significant decrease of about 4.5% and 2.8% higher decrease in systolic and 
diastolic blood pressure were reported as compared to control groups. This study suggests that 
including blueberry as a dietary supplement might help in reducing the risk factors related to 
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cardiovascular disorders and reducing the intensity by a certain extent (168). Hypertensive rats 
on 2% w/w blueberry enriched diet for 6 to 12 weeks were reported to have lower blood 
pressure, improved glomerular filtration rate, and decreased renovascular resistance as compared 
to control groups. Long-term blueberry diet also showed significant decrease in total reactive 
oxygen species (ROS), peroxynitrite, and superoxide production rates kidney tissues (169). The 
results suggest that including blueberries in diet could prove beneficial for individuals suffering 
from hypertension. 
Antiobesity: Obesity and its prevalence has increased significantly over the last few decades 
with the consumption of high fat diet and lack of exercise and sedentary lifestyle. Polyphenols 
present in green tea, grape seeds, orange, grapefruit and berries are known to have anti obesity 
effects (170). Antiobesity effects of blueberry juice were recently demonstrated in mice on a 
high fat diet (171). Four-week-old C57BL/6 mice were fed a high-fat diet (HFD) with or 
without blueberry juice for 12 weeks. Consumption of blueberry juice was shown to reduce the 
body weight of the mice by 7.3%. Liver lipids were reported to be ~ 10mg/ml lower in levels in 
blueberry juice fed rats as compared to HFD controls. Thus consumption of blueberry juice 
could help in tacking obesity issues (171). In a study dose-dependent effects 
of blueberry polyphenols were studied on mouse 3T3-F442A preadipocytes where 
blueberry polyphenols at concentrations of 150, 200, and 250 μg/mL led to a reduction of 27%, 
63%, and 74% in intracellular lipid content respectively as compared to the control. All three 
concentrations of blueberry polyphenols were also reported to have significant inhibition of cell 
proliferation(170). 
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Bioavailability and delivery: Pastes, gel, powders can be potential delivery methods for 
targeting gastrointestinal conditions. Insuring bioavailability for any potential application is also 
an important consideration. Bioavailability of anthocyanins has been reported to be very low in 
human volunteers. A study carried out showed that when doses of 150 mg to 2 g total 
anthocyanins were given to the volunteers in the form of berries, berry extracts, or concentrates, 
levels of anthocyanins in plasma detected thereafter were reported to be as low as 10–50 nmol/L 
(172). Thus there is a need to develop effective delivery systems to ensure the delivery of 
bioactives.  Antioxidant capabilities of blueberry and cranberry were investigated under 
simulated conditions of GI tract were demonstrated, where berry homogenates first exposed to 
digestive enzymes and then exposed to CaCo-2 cells did not show significant reduction in the 
antioxidant activity (173). Also, these treated homogenates were shown to annul the effects of 
ROS (reactive oxygen species) generated by hydrogen peroxide (173). Such critical evaluations 
are necessary to develop better delivery methods to the gut by way of encapsulation or controlled 
release so as to protect the beneficial properties from the gut enzymes and acids. More studies 
need to be carried out to validate its safety via feeding studies and clinical trials. 
Grape seed extract 
Grapes (genus Vitis) are native to southern Europe and Western Asia near the Caspian 
Sea, and were brought to North America and Europe. The medicinal and nutritional properties of 
grapes have been well known over centuries, where Egyptians and Greeks used the various 
forms of grapes (ripe, unripe, dried) in healing of various health conditions. Grape seed extract 
(GSE) is a natural by-product of the wine and grape juice processing industries (174). Grape seed 
and grape skin has been shown to contain bioactive components such as flavonoids, polyphenols, 
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anthocyanins, proanthocyanidins, procyanidins, and the stilbene derivative, resveratrol (175). 
Grape seeds are also known to have high amounts of monomeric phenolic compounds, such as 
epicatechin, epicatechin-3-O-gallate, catechins, and dimeric, trimeric and tetrameric 
procyanidins (176). Several pharmacological and therapeutic benefits such as antimicrobial, anti-
inflammatory, antioxidative, cardioprotective, and neuroprotective effects have been reported to 
be associated with GSE (177). GSE has been approved as a generally recognized as safe (GRAS) 
by the U.S. Food and Drug Administration and hence is being studied extensively for its use as 
an antimicrobial agent in foods. ("GRAS" is Generally Recognized As Safe under sections 
201(s) and 409 of the Federal Food, Drug, and Cosmetic Act) (178). GSE at doses of 50 to 100 
mg/ml per day do not exhibit toxicity or adverse health effects in rats (176, 179, 180). This adds 
advantages to GSE that has great potential for use as a value-added product associated with its 
low cost, sustainability, and lack of evidence of being hazardous to the environment.  
Antibacterial effects of GSE: GSE (both methanol and acetone extracts) were found to be more 
effective against Gram-positive bacteria when compared to Gram-negative bacteria, when tested 
against several foodborne bacterial pathogens (175).The minimum inhibitory concentration 
(MIC) with a methanol:water:acetic acid (90:9.5:0.5) extract was found to be 900 ppm for the 
gram-positive Bacillus cereus, Bacillus subtilis and Bacillus coagulans and 1000 ppm for 
Staphylococcus aureus (175).For the gram-negative Escherichia coli and Pseudomonas 
aeruginosa, the MIC was found to be 1250 and 1500 ppm, respectively. When the extract 
contained acetone (acetone: water: acetic acid (90:9.5:0.5)) instead of methanol, differences in 
MIC were observed for the gram-positive bacilli, resulting in MICs of 850 ppm for B. cereus, B. 
subtilis and B. coagulans, while the other organisms showed similar MICs to the methanol: 
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water: acetic acid (90:9.5:0.5) extract. These researchers determined that gallic acid was the 
bioactive component, with the three hydroxyl responsible for the antibacterial activity of GSE 
(175). Muscadine grape skin extracts were also found to be effective against Helicobacter pylori 
(causative agent of ulcers) with MIC ranging from 256 to 512 g/ml, and the MIC ranged between 
256 to 1,024 g/ml for muscadine seeds (181). Resveratrol and ellagic acid were also found to 
inhibit this ulcer causing bacteria, with an MIC range of 6.25 to 50 g/ml, while myricetin was 
found to have no effect (181). GSE at a concentration of 5 mg/ml was also found to inhibit the 
dihydrofolatereductase activity and growth of S. aureus at 0.5 mg/ml after 6 h, however some 
injured cells were recovered after 12 h (182). For GSE at 1 mg/ml, these researchers reported 
99% of inhibition after 24 h, with no observed cell recovery.  
 In another study, commercial grape juice and skin and grape seed extract were tested 
against the gram-positive foodborne pathogen, Listeria monocytogenes, of concern to 
immunocompromised individuals and pregnant women. Commercial grape juice decreased L. 
monocytogenes from 10
6
 –107 CFU/ml to undetectable levels and B. cereus by 1-log within 10 
min in the juice, without further reduction after 60 min (183). The seed and skin extracts (250–
280 mg/L gallic acid) were reported to have similar anti-listerial activity to that of the 
commercial grape juice (183). Anti-bacterial activity of GSE was also tested against methicillin 
resistant S. aureus (MRSA), which is an on-going problem in nosocomial and other related 
infections, where health-care providers continue to have challenges in prescribing appropriate 
antibiotics against these infections (184). All of the 43 MRSA strains tested were found to be 
inactivated at 20.67 µg of GSE flavonoids (184). Another study showed that GSE at 1 and 5 
mg/mL was found to be effective against MRSA strains resulting in a 2.9-4.0 log CFU/ml 
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reduction after 2 h at 37°C (145). These results suggest that natural products such as GSE can be 
used as effective antimicrobials for multidrug resistant strains as an alternative to regular 
antibiotics.  Red GSE at 0.5 mg/ml was found to reduce plaque formation of Streptococcus 
mutans in vitro by 40% as compared to control (185), showing the potential of GSE to prevent 
dental caries.  
 
Antiparasitic effects of GSE: GSE has been reported to have antiparasitic effects against 
Histomonas meleagridis, a protozoan parasite responsible for histomonosis with high mortality 
in turkey and chicken (186); Blastocystis, a prevalent unicellular parasite in human fecal 
specimens (187); Trichomonas gallinae that causes avian trichomonosis in various bird species, 
especially pigeons and doves (188); and Trichostrongylus colubriformisa parasite of herbivorous 
mammals (189). GSE at 100 ppm for 6-12 h was shown to kill 50% of exposed Lymneacailliaudi 
snails (LC50; lethal concentration 50) with higher molluscidal activity with increased exposure 
time to 12-24 h (190). However GSE showed weak effect against Culex pipiens larvae 
(responsible vectors for malaria, dengue and yellow fever) where their mortality did not increase 
over 50% even after increasing the GSE concentration to more than 200 ppm for 48h (190). GSE 
at 5 mg/ml was also found to completely inhibit (initial number of 10
3 
histomonads) the growth 
of Histomonas meleagridis, Trichomonas gallinarum and Blastocystis sp. after 24 and 48 h 
(191). Another study tested a new product containing GSE against the avian parasite H. 
meleagridis, that showed inhibition of its growth at concentration of 2.5 or 5 µl/ml after 48 h 
(192). GSE at 10-20 mg/kg was reported to reduce mortality in chickens infected with Eimeria 
tenella and also alleviated the oxidative stress following infection and helped improve the weight 
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gain of chickens which is important for the poultry industry (193). Flavan-3-ols and galloyl 
derivatives of condensed tannins that are components of GSE were found to be completely 
inhibitory towards egg hatching of Trichostrongylus colubriformis at 1000 mg/ml, and 
epigallocatechin gallate at 100 mg/ml showed 100% inhibition of T. colubriformis larval 
development (194). Methanol extracts of grape seed at 300 and 600 mg were reported to be 
effective in killing the immature form of the leech Limnatis nilotica within 260 and 200 min, 
respectively, but was not effective towards the mature forms, suggesting that GSE should be 
used in combination with other treatments to boost their anti-leech effects (195).  
Antiviral activity of GSE: In addition to bacteria, GSE is known to have effects against several 
viruses of human health concern. Human noroviruses are recognized as leading causes of non-
bacterial gastroenteritis worldwide (3, 196). However, since these non-enveloped single-stranded 
RNA containing human noroviruses cannot be cultivated in the lab, cultivable surrogates such as 
feline calicivirus (FCV-F9) and murine norovirus (MNV-1) are used to determine inactivation by 
various chemical or processing technologies (197). Hepatitis A virus is another non-enveloped 
single-stranded RNA containing foodborne virus important because of the severity of the disease 
that affects the liver and lasts for more than a month. GSE at 0.25, 0.5, and 1.0 mg/ml for 2 h at 
37°C was shown to reduce FCV-F9 titers by 3.64, 4.10, and 4.61 log PFU/ml; MNV-1 by 0.82, 
1.35, and 1.73 log PFU/ml; and HAV by 1.81, 2.66, and 3.20 log PFU/ml (197). GSE was also 
shown to prevent replication of human norovirus surrogates using ELISA studies that were in 
agreement with the earlier studies of Su et al., 2011, where MNV-1 titers were shown to be 
reduced by 3 log PFU/ml when treated with 0.2 mg/ml (144). GSE was also evaluated for its 
anti-noroviral activity as a surface disinfectant by these researchers, where 0.2 mg GSE/ml, 
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showed a reduction of MNV-1 to undetectable levels without the presence of any protein load. In 
presence of 0.01% dried milk, reduction to undetectable levels was obtained only with 2 mg/ml 
GSE, while in tap water, GSE at 0.2 and 2 mg/ml was shown to cause 1 and 2 log PFU/ml 
reduction in MNV-1 titers (144). The effect of the symptoms of HIV-1 and AIDS is well 
publicized, emphasizing the need for improved control and preventive measures, where GSE 
may play an important role. GSE is also reported to interfere with the binding of the AIDS 
causing human-immunodeficiency virus (HIV-1) to its host cell receptor and thus prevents HIV-
1 entry into the normal lymphocyte (198). 
Mechanism of action of GSE against microbial pathogens: With regards to antibacterial 
properties of GSE, the bacterial cell membrane being semipermeable allows the entry of 
polyphenols that can interact with the cytoplasm or cellular proteins, with higher ability of GSE 
polyphenols (that are present in undissociated forms) to enter the cell and interact with cellular 
components (199). Thus, the benefits of the antimicrobial properties of GSE can be exploited for 
food or clinical applications. GSE was shown to have some effect on viral adsorption of FCV-
F9, MNV-1, and HAV, with less effect on replication (197). These researchers showed that when 
the respective host cells were treated with GSE before viral infection, the titers of FCV-F9, 
MNV-1, and HAV were decreased by 0.8, 0.5, and 1.9 log PFU/ml, respectively. GSE treatment 
after the viral infection of the host cells showed a 0.1, 0.2, and 0.8 log PFU/ml reduction, 
respectively.  The higher reduction obtained by GSE when used in pre-infection than post-
infection, indicated that GSE either blocks virus binding to the host cell receptors or coats the 
virus to prevent attaching to the host-cell or causes clumping of viral particles. GSE has also 
been shown to inhibit the replication and expression of HIV-1, an enveloped virus with 
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glycoproteins gp 120 and gp41, by blocking binding of HIV-1 to the cell receptor and preventing 
HIV-1 entry into the normal lymphocyte (198). The study also showed that GSE at 
concentrations of 0.5 to 5 mg/ml over 24 h at 37°C was found to significantly down regulate 
expression of HIV-1 co-receptors, CCR2b and CCR3 (B- chemokine receptors), in peripheral 
blood mononuclear cells (198).  
Resveratrol (RV) is a non-flavonoid polyphenol found in grape seed and grape skin and is 
known to be synthesized in response to external stimuli and injury (200).  RV has been known to 
affect several intracellular signaling pathways, and strongly inhibits the in vitro and in vivo 
replication of influenza virus (201). Virus replication was reportedly reduced by 20 μg/mL of RV 
and completely inhibited by 40 μg/mL of RV over 72 h of infection time. RV at 20 µM was also 
found to inhibit the replication of polyomavirus, with complete reduction of replication after 24 h 
of infection (202). Polyomaviruses are small, double stranded DNA viruses known to occur in 
immunocompromised individuals and may cause hemorrhagic cystitis in recipients of bone 
marrow transplantation and progressive multifocal leukoencephalopathy (203). 
Studies were also carried out to gain insight about the mechanism of action of GSE and 
its components against bacterial pathogens, and it was proposed that the antibacterial activity of 
tannins could be due to the inhibition of extracellular microbial enzymes (146). Inhibitory effects 
of GSE could also be attributed to the constituent phenolic compounds that can form phenoxyl 
radicals upon entering the cell, or binding to the cellular membrane and causing cellular 
disruption (204). In addition, scanning electron microscopy studies carried out on MRSA cells 
treated with GSE showed the that the cell surface was rough and disrupted in comparison to the 
smooth and rounded surfaces of control cells (145). This suggests that GSE may be acting by 
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disrupting the bacterial cell membrane causing leakage of cellular material and thereby 
inactivation. In addition to the antimicrobial properties of GSE, research on other health benefits 
is also being carried out extensively. 
Role of GSE in Anti-inflammation: Inflammation is theorized to be the underlying cause of 
most health issues and chronic inflammation has been linked to heart disease, hay fever, 
rheumatoid arthritis, obesity, and diabetes (205-208). When the anti-inflammatory and 
antioxidant properties of GSE were investigated in the case of septic shock caused by the 
intraperitoneal injection of lipopolysaccharide (LPS) derived from Escherichia coli, GSE at 
doses of 75 mg/kg/day had anti-inflammatory effects by decreasing the nitrate and nitrite (NOx) 
levels in the plasma, red blood cells, spleen, and liver (209). These researchers showed that high 
doses of 200 mg/kg/day could down regulate the genes Il-6 (interleukin 6) and iNos (inducible 
nitric oxide synthase) associated with inflammatory responses against the LPS endotoxin (209). 
Murine studies showed that when GSE at 100 mg/kg was administered to acute asthmatic mice, 
there was a decrease in number of eosinophils, airway inflammation, hyper responsiveness, and 
oxidative stress (210). 
GSE and its effects on Atherosclerosis and Heart Disease: GSE has been widely studied for 
their cardio-protective properties, and in reducing cholesterol and plasma lipoproteins. For 
example, GSE was shown to alleviate the side effects such as cardiac steatosis (adipose 
degeneration) and lipotoxicity in rats fed on a high fat diet for 45 days at levels of 500 
mg/kg/bodyweight (211). GSE at doses of 50 and 100 mg GSE/kg body weight were found to 
reduce 49 and 63% foam cells, a biomarker of early stage atherosclerosis (212). Red grape seed 
extract at 200 mg/day for 8 weeks was found to reduce total cholesterol and oxidized low-density 
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lipoprotein particles by 10.68 mg/dL and 5.47 mg/dL, respectively (213). Thus, GSE 
consumption may also prove to be beneficial in reducing the risk of atherosclerosis (213). 
Additionally, dry GSE at a concentration of 100 mg was found to significantly decrease the 
amount of serum cholesterol levels in human volunteers (214). Taken together, these studies 
show the anti-atherosclerotic and cardio-protective effects of GSE. 
GSE and its role in obesity and diabetes: GSE has also been explored for use in controlling 
obesity and preventing diabetes.  Lipoprotein lipase (LPL) is an enzyme involved in hydrolysis 
of triacylglycerol by releasing free fatty acids for uptake into adipocytes, involved in obesity. 
GSE at 1 mg/ml was found to inhibit human pancreatic lipase activity by almost 80% within 5 
min of incubation in adipocytes, suggesting the benefits of GSE against obesity (215). GSE was 
also found to up-regulate Tregs (regulatory T cells) and T helper 2 cytokine producing cells that 
play a role in suppressing excessive immune responses (216). 
GSE was also shown to reduce postprandial plasma glucose in healthy individuals, where the 
plasma glucose concentrations at 15 min and 30 min after consumption of a high carbohydrate 
meal with 100 mg or 300 mg of GSE was significantly lower than that of a high carbohydrate 
meal without GSE (217). The study proposed the use of GSE as a preventive measure against 
diabetes in otherwise healthy populations. Mice on a high fat diet were shown to be protected 
from nerve fiber loss compared to controls when administered 100 mg/ml GSE for 12 weeks, 
suggesting that GSE may provide benefits towards the treatment of diabetic neuropathy (218). 
Antioxidative effects of GSE: GSE is known to be an efficient antioxidant and free radical 
scavenger (175). GSE at 50 mg/l was shown to be an effective radical scavenger, being better 
than vitamins C and E (219). GSE components like procyanidin B4, catechins, and gallic acid at 
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concentrations of 10-25μmol/l were reported to be good preventive agents against cellular DNA 
oxidative damage, though, these compounds may induce cellular DNA damage at higher 
concentrations of 150 μmol/l (220). GSE at 2 mg/ml was found to inhibit the peroxidation of 
polyunsaturated fatty acids induced by UV–C (221). 
Anticarcinogenic effects of GSE: When grape seed polyphenols were investigated for their 
anti-carcinogenic effects towards 12-O-tetradecanoylphorbol-13-acetate-(TPA)-induced tumor 
reduction as a topical application, tumor incidence was inhibited by 35 and 60%, tumor 
multiplicity was inhibited by 61 and 83% and tumor volume was inhibited by 67 and 87% at 
concentrations of 0.5 and 1.5 mg/ml/mouse/application on mouse skin (222). More recently in 
breast cancer studies, GSE at 100 μg/ml was found to increase apoptotic cell death significantly 
by up to 12% after 72 h incubation, when the highly metastatic MDA-MB 231 breast cancer line 
was used (223). Grape powder, resveratrol, and GSE when administered topically 30 min after 
7,12-dimethylbenz [a] anthracene (DMBA, a skin carcinogen) exposure at concentrations of 1, 2, 
or 4 mg was shown to inhibit epidermal hyperplasia, proliferation, and dermal inflammation 
(224). GSE at 50 μg/mL was also reported to significantly induce apoptotic death in non-small-
cell lung cancer cell lines by causing a release of cytochrome c in the cytosol and cleavage of 
caspases 3 and 9 that play a role in cell death (225). 
Potential application of GSE for food industry as produce wash: Natural products that are 
cost-effective, environmentally friendly, and sustainable are of great interest to the food industry. 
GSE is one such natural product, which is being investigated as an antimicrobial surface 
disinfectant. Several studies have aimed to evaluate the potential of GSE for its use as a food 
additive or a pre-packaging wash or treatment. Kao et al., 2011 used pork slices as a “model” 
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food to evaluate its use in the food industry. Pork slices were first immersed in 20 mg/ml, 60 
mg/ml, or 100 mg/ml of GSE solutions and then inoculated with S. aureus suspensions, and 
incubated at 37°C for 8 h and 24 h, after which >99% of inhibition was observed for pork slices 
treated with 100 mg/ml GSE (182). However, with such high concentrations of GSE used (due to 
its bitter taste), it is important to note that there may be issues with sensory acceptance of these 
products by consumers. In another study by Corrales et al., 2009, GSE was introduced into pea 
starch films at a concentration of 1% that showed growth inhibition of Brochothrix 
thermosphacta (spoilage organism) by 1.3 log CFU/mL in pork loins during the first 4 days of 
incubation (226). When GSE (commercially available Gravinol-S) was tested as an antimicrobial 
wash on fresh produce, MICs for Listeria monocytogenes and L. innocua ATCC 33090 were 
found to be 50 and 78 µg/ml (227). When tested against live cells using flow cytometry at sub-
MICs for 2 min, GSE was found to cause rapid permeabilization and clumping of L. innocua.  
GSE treatment of 1250 µg/ ml was shown to yield the highest reduction of L. monocytogenes by 
2 log CFU/ml after 2 min on spiked Roma tomatoes. These results suggest the potential 
application of GSE as a surface disinfectant for fresh produce (227). Conventional and 
electrostatic spraying of malic acid (MA), tartaric acid, gallic acid and GSE against Salmonella 
Typhimurium using spinach as a model system, showed that MA alone sprayed electrostatically 
caused reductions of 1.6 and 3.2 log CFU/g after 7 and 14 days, while GSE alone led to a 
reduction of 0 to 1.4 log CFU/g (228). These researchers reported that maximum reduction of 2.6 
to 3.3 log CFU/g was observed for spinach leaves treated with 2% malic acid in combination 
with 3% GSE when sprayed electrostatically, while lower log reductions were observed (0 to 1.5 
log CFU/g) when sprayed conventionally (228). These results showed that electrostatic 
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combination sprays containing MA and GSE were more effective in reducing the foodborne 
gram-negative S. Typhimurium that is linked to on-going produce outbreaks. 
Consumer concerns regarding addition of nitrite in processed meats has led to finding 
natural alternatives such as GSE (142). GSE at 0.5% was found to reduce L. monocytogenes by 
1.1 log CFU/g after 9 days at 10
o
C in cured meats (142). When fresh pork slices that were first 
treated with GSE along with oregano, clove and pomegranate and then inoculated with low (10 
CFU/m1) and high (10
5
 CFU/mL) titers of L. monocytogenes, S. aureus and S. enterica, 
aerobically packed and stored at 20
O
C, the treated samples showed reductions of 1.36, 0.96 and 
1.75 log CFU/g for L. monocytogenes, S. aureus, and S. enterica, respectively after 9 days (179). 
Irradiated meat samples when treated with a single 1% GSE treatment led to a reduction 
from of 6.5 to 4.5 log CFU/ml L. monocytogenes in 12 to 18 h but no subsequent further 
reduction were observed; while nisin (6400 IU/ml) treatment gave an initial reduction of 3 log 
CFU/ml in 12 h though the cell numbers rebounded after 18 to 24 h (180). However, these 
researchers showed that the combined treatment with 1% GSE and nisin (6400) IU led to 
reduction below detectable limits (180). 
Application of GSE as an antiviral produce wash was also studied where 0.25 to 1 mg/ml GSE 
was found to reduce FCV-F9 and MNV-1 titers within 5 min on spiked lettuce and peppers 
(229). High titers (~7 log PFU/ml) of FCV-F9 on lettuce and peppers were found to be reduced 
by 2.71 log PFU and 3.05 with GSE at 1 mg/ml after 1 min, respectively, while MNV-1 was 
shown to be reduced by 0.2-0.3 log PFU on lettuce and 0.8 log PFU on peppers for low titers (~5 
log PFU/ml) (229).  
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Pomegranate polyphenols 
Pomegranate (Punica granatum) is a plant native to Iran, India, and the Mediterranean countries 
such as Turkey, Egypt, Tunisia, Spain, and Morocco (230). Pomegranate juice and its peel are 
known to be a rich source of polyphenols including flavonoids (anthocyanins, catechins and 
other complex flavonoids) and hydrolyzable tannins (punicalin, pedunculagin, punicalagin, gallic 
and ellagic acid), which account for 92% of the antioxidant activity associated with the fruit 
(231). Among these, Ellagitannins and punicalagins were reported to be the main bioactive 
fractions in pomegranate (232). The anthocyanin content in pomegranate juice was shown to be 
around 135 mg/L; punicalagins and punicalins content were shown to be between 80 and 
135 mg/L (233). In addition, it is also known to contain organic acids such as ascorbic acid, citric 
acid, fumaric acid, and malic acid (230).Methanolic extract of pomegranate was shown to inhibit 
the formation of biofilms by S. aureus, methicillin resistant S. aureus, Escherichia coli, and 
Candida albicans where the reported MIC was 1000µg/ml (234). The extract also disrupted pre-
formed biofilms of C. albicans. Pomegranate extracts were also examined for their antimicrobial 
effects against Clostridium difficile, where the effective minimum inhibitory concentration 
ranged in between 12 to 25 mg/ml gallic acid equivalent (235). Aqueous pomegranate extracts 
were demonstrated to have activity against E. coli O157:H7 with an MIC of 0.19 mg/mL (236). 
Studies have proposed that the mode of action of pomegranate polyphenols is by disrupting the 
cellular membranes, inhibiting microbial enzymes and through interaction with proteins and co-
aggregation of microorganisms (237, 238). Pomegranate extract was shown to have antifungal 
properties, where the crude extract at 5 mg/ml inhibited Stemphylium botryosum spore 
germination by 74% (232). Effect of purified pomegranate extract on influenza virus was studied 
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where punicalin (tannin) was shown to inhibit the virus replication and also inhibited 
agglutination of chicken red blood cells by the virus, and, when used in combination with the 
antiviral oseltamivir (237). Pomegranate polyphenol powder extract at 800 µg/ml was shown to 
reduce influenza virus titers by 3 log at room temperature within 5 min and it was suggested that 
this antiviral activity could be owing to the coating of the virus (239). In addition, pomegranate 
polyphenols were also shown to inhibit replication of Human immunodeficiency virus (HIV-1) 
by blocking the virus binding to CD4 host cell receptors (240).   
Pomegranate juice was demonstrated to reduce titers of human norovirus surrogates; FCV-F9, 
MNV-1, and MS2 by 1.20, 0.06, and 0.63 log PFU/mL respectively at room temperature after 1h 
(241). When treated with polyphenols from pomegranate a reduction of 1.30, 2.11, 3.61 
logPFU/mL for MNV-1 was obtained with 8, 16, and 32 mg/mL within 1h at room temperature. 
Titers of FCV-F9 were reduced to undetectable levels with 8 mg/ml within 1h at room 
temperature. The study suggested that this antiviral effect could be due to the possible binding of 
the polyphenols to the virus particle or by blocking host cell receptors (241).  
Cranberry polyphenols 
Cranberries (Vaccinium macrocarpon) are native to North American region and contains diverse 
group of phytochemicals, including flavonoids, hydroxycinnamic acid derivatives, organic acids, 
and isoprenoids including ursolic acid and lutein(242). The predominant bioactive compounds 
found in cranberries are the flavonols, the flavan-3-ols, the anthocyanins, the tannins 
(ellagitannins and proanthocyanidins), and the phenolic acid derivatives. The average flavonol 
content in cranberry is 410mg/100 g fresh fruit weight (243). Cranberries have a high amount of 
oligomeric and polymeric pigments, also referred to as condensed non-hydrolyzable tannins or 
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proanthocyanidins (PAC). 51-90% of the PAC’s in cranberries are A-type PAC’s. A-type 
PAC’shave anti-adhesion activity against the urinary tract infection causing P-fimbriated E. coli 
to uroepithelial cells and decrease in the expression of P-fimbrial gene (244). Commercial 
cranberry juice (CJ, pH 2.5) was found to reduce common gastrointestinal bacterial pathogens, 
E. coli O157:H7 and L. monocytogenes at 8 log CFU to undetectable levels after 15 min and 1 h 
of treatment at -23
o
C (storage conditions) respectively. Cranberry proanthocyanidins (CPACs) at 
25 mg/ml were found to inhibit infection and invasion of epithelial cells by enteropathogenic 
Escherichia coli (EPEC) and Salmonella Typhimurium by preventing the formation of actin 
pedestal required by EPEC for host infection (245). CJ was also found to inhibit biofilm 
formation of E. coli, L. monocytogenes, Campylobacter jejuni, S. Typhimurium and S. aureus. It 
was shown that CJ reduced the non-specific adhesion of bacterial cells to borosilicate glass 
(246). Oregano–cranberry (50:50) extracts at a concentration of 750 ppm in combination with 
2% sodium lactate were shown to inhibit growth of L. monocytogenes by 1 log CFU/ ml in 
cooked ground beef samples. It was reported that in presence of 1mM proline, the effect of 
Oregano–cranberry with sodium lactate was significantly reduced indicating proline 
dehydrogenase to be the likely site of action for phenolic phytochemicals and lactate radical 
(247). In a similar study, cranberry juice was shown to reduce aerobic plate count for coliforms 
initial ~7 log CFU/ cm2 to 3.86 CFU/cm2 on chicken breasts (248). Studies on anti-adhesive 
effect of cranberry PAC on E. coli to uroepithelial cells showed that stationary phase strains was 
found to be about 52% and 75.5% inhibited in the presence of 100 μg/ml cranberry PAC A2 in 
pretreated uroepithelial cells (249). Cranberry proanthocyanidins (CPAC) at 1 mg/ml were also 
shown to reduce methicillin resistant Staphylococcus aureus (MRSA) ATCC 33591 by 1.04, 
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1.68 and 1.84 log10 CFU/ ml after 1, 2 and 8 hours of treatment respectively. Complete 
reduction was shown after 24 hours at 37
0
C, however MRSA ATCC 33593 was reported to 
reduce completely within 8 hours of treatment with 1mg/ml CPAC (145). 
Cranberry juice (CJ) at concentrations ranging from 50%, 30%, and 10%, was shown to reduce 
bacteriophages T2 and T4 of E. coli strains C and B, and also simian rotavirus SA-11 after 30 
min at 37
o
C, 23
o
C and 4
o
C from 9 log PFU/ml to undetectable levels by plaque assays (101). 
However, concentrations lower than 10% did not show any significant reduction. Scanning 
Electron Microscopy (SEM) studies showed that CJ treated phage T4 was unable to attach to 
bacterial host cells as opposed to the control. Cranberry juice was also shown to inhibit 
hemagglutination of rotavirus, where 20% CJ led to a complete hemagglutination inhibition. It is 
proposed that CJ led to a change in glycoprotein moieties, which led to a failure in virus binding 
the receptor cells (101). Cranberry juice and cranberry PAC (proanthocyanidins) were also found 
to reduce human noroviral surrogates murine norovirus (MNV-1), feline calicivirus (FCV-F9), 
MS2 bacteriophage, and phiX-174. Cranberry juice at pH 2.6 and 7, and CPAC at 0.15 mg/ml 
and 0.3 mg/ml was shown to cause a complete reduction of FCV-F9 within 30mins. CJ at pH 
2.6, 7.0 and CPAC at 0.15 mg/ml, 0.30 mg/ml PAC was found to cause log reductions of 1.90, 
1.66, 2.24 and 2.94 log10 PFU/ml after 1h for MNV-1, respectively. For phi-X 174, reduction in 
titers of 1.66, 1.24, 2.15 and 2.82 log10 PFU/ml was achieved after 1 h with CJ at pH 2.6, CJ at 
pH 7.0, 0.15 mg/ml PAC and 0.30 mg/ml PAC (250). 
Raspberries 
Black raspberry (Rubus coreanus) is native to South Asian countries including China, Japan and 
Korea. They are known for their anti-inflammatory, antibacterial, and antiviral properties. The 
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fruit contains polyphenolic compounds including gallic acid and quercetin (251). When screened 
for their antibacterial activity, black raspberry was shown to effective against multi drug resistant 
Staphylococcus aureus (MRSA), Bacillus anthracis and Acinetobacter baumannii (252). MIC’s 
of 250, 125 and 1000 µg/ml were reported for MRSA, B. anthracis and A. baumannii, 
respectively. At 1% concentration, raspberry extract caused 80% inhibition on the growth of 
Helicobacter pylori (150). Black raspberry juice (6%) was also shown to have antiviral effect on 
the HNoV surrogate, MNV-1 causing reduction in plaque titers by 99% after 1 h (253). Co-
treatment (simultaneous addition of treatment and virus to the host cells) was demonstrated to 
exert maximal antiviral activity on bothFCV-F9 and MNV-1. The study suggested that the juice 
exerted its antiviral effect by inhibiting viral attachment to host cells, though gallic acid and 
quercitin did not have any significant effect (253).  
 
Blackberries 
Blackberry (Rubus fruticosus) fruits and plants have been used in herbal medicine for their 
antimicrobial, anticancer, antidiabetic, antidiarrheal, and antioxidant 
properties(254). Blackberries contain phenolic compounds including tannins, gallic acid, 
anthocyanins along with vitamin C, niacin, sugars, and some amounts of, citric acid and malic 
acid (255). Blackberries were shown to reduce the oral pathogen Fusobacterium nucleatum by 
1.5 log CFU with 1400 µg/ml of blackberry extract after 24h at 37
o
C (255). . Metabolic activity 
of F. nucleatum was reported to reduce by 40% with 700 μg/mL of blackberry extract, while a 
higher concentration of 1400μg/mL caused the metabolic activity to reduce by 84% (255). 
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Extract from blackberry leaves were reported to have minimum bactericidal concentrations 
(MBCs) against H. pylori strains G21 and 10K of 1200 µg/mL and 1500 µg/mL after 24h and 
134 µg/mL and 270 µg/mL after 48 h, respectively(256). Blackberry extract at 56 μg/mL was 
also shown to inhibit herpes simplex virus (HSV-1) replication in oral epithelial cells by 
99%(255). Higher concentration of 280 μg/mL was shown to affect the virus adsorption and 
entry into host cells.  
Hibiscus extracts 
Hibiscus sabdariffa commonly known as ‘roselle’ is an annual, tropical or subtropical shrub 
species native to countries including Sudan, Mexico, India, and Thailand. It belongs to family 
Malvaceae and calyces are often used in the preparation of beverages or for ornamental purposes 
(Morton, 1987). Hibiscus calyces contains bioactive compounds including anthocyanins, 
phenolic acids, organic acids, saponins, and alkaloids, gallic, chlorogenic, and protocatechuic 
acid and these flavonoid compounds are responsible for the deep red color of the calyces (257, 
258). The total phenolic content is around 77.2 mg GAE (gallic acid equivalents)/g for an 
aqueous extract and 87.7 mg GAE/g for an ethanol extract (259). The calyces (aqueous extracts) 
are considered GRAS (generally recognized as safe) and are approved for use as a food additive 
by the U.S. by the Food and Drug Administration (21 CFR 172.510) in the flavoring of 
beverages. Delphinidin-3-sambubioside and cyanidin-3-sambubioside are two anthocyanins 
found in hibiscus extract that also contribute towards the antioxidant activity (260). Other 
compounds present are gossypetin, quercetin, pectin, saponins, cardiac glycosides, and alkaloids 
(261). These organic acids may also contribute to the antimicrobial activity, where the 
undissociated form of the organic acid can enter the cell wall of bacteria, thereby stressing the 
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cell by pH reduction cell and can lead to death (262). Organic acids including malic acid and 
tartaric acid are also identified in the calyces resulting in the low pH of approximately 2-2.5 
(263). Calyces of H. sabdariffa are known to possess a wide range of health benefits including 
antioxidant, anti-diabetic, anticancer, cardio-protective and antimicrobial effects (264-266). 
Aqueous extracts were also shown to be effective against methicillin-resistant S. aureus, 
Klebsialla pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii with the MIC’s 
of 32, 48, 56 and 48 mg/l respectively (267). Crude extracts of H. sabdariffa calyces were 
reported to be effective against Propionibacterium acnes and Staphylococcus epidermidis, where 
the MIC was reported to be 2.5 mg/ml and 0.625 mg/ml, respectively and MBC (minimum 
bactericidal concentration) were reported to be to 5 mg/ml for both (268).  Ethanol and aqueous 
extracts of H. sabdariffa were also shown to have inhibitory effects against foodborne bacteria 
such as E. coli O157:H7, Salmonella Typhimurium, Listeria monocytogenes, Bacillus cereus, 
and S. aureus when added at levels of 5 or 10 mg added to 100 g ground beef or 100 ml apple 
juice after 3 days of storage (269). Another study showed that the aqueous extracts at 100 % v/v 
when used as a produce wash could reduce 4 log CFU/g of E. coli O157:H7 and Salmonella 
enterica on lettuce after 24 h (270). In a recent study, H. sabdariffa extracts at concentrations of 
0.5 to 2 mg/ml were also shown to inhibit biofilm formation in Candida albicans (271). 
Protocatechuic acid (PCA) is an essential component of H. sabdariffa and has been demonstrated 
to have several health beneficial properties (272). PCA has been shown to be the active 
component responsible for the antimicrobial activity of H. sabdariffa (267). Ferulic acid, a 
component of Hibiscus mutabilis has also been demonstrated to have antimicrobial properties 
against common food borne bacteria including E. coli, S. aureus and L. monocytogenes (273). 
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Ferulic acid was also demonstrated to possess antifilarial activity against Setaria cervi (274). 
Conclusions 
Overall, natural plant polyphenols appear to be promising alternates for use as preventive, 
therapeutic or control options against the spread of foodborne illness. It is recognized that 
effectiveness of antimicrobials can decrease in the presence complex food matrices where 
components of foods such as lipids, proteins or other acidic or alkaline conditions may interfere 
in the antiviral properties. Hence, it is necessary to determine their effects in model food 
systems, environment, and in simulated gastrointestinal fluids to better understand their effects 
and applications. To mimic the survival and behavior of viruses and antivirals in the gut, survival 
studies using simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) are necessary. 
Survival studies in gastric environments have been reported previously with foodborne bacterial 
pathogens such as E. coli, L. monocytogenes and V. vulnificus (275-277). Apple juice and milk 
were chosen to study the effectiveness of tested treatments in this study. Apple juice is a food 
product mainly consisting of carbohydrates (sugars including glucose, fructose, sucrose and 
sorbitol), nonvolatile acids (malic, quinic, citric, shikimic, and fumaric), and phenolics 
(chlorogenic acid and hydroxymethylfurfural) (278). In a study, cinnamon bark essential oil at 
1,000 was shown to have bactericidal against L. monocytogenes with 3 log CFU/ml reduction in 
skimmed milk and 1 log CFU/ml reduction in whole milk (279). The study suggested that 
intrinsic parameters like fat and protein contents of the milk interact with the antimicrobial 
substances that might reduce their activity. In addition to studying the effectiveness of these 
antivirals in foods systems and the gut environment, it is also interesting to look into their 
inactivation mechanisms. Several attempts have been made at understanding the mode of 
antiviral action against these noroviral surrogates using various techniques like electron 
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microscopy studies, binding studies, molecular assays and in vitro cell culture assays (144, 197, 
253). Viruses are known to cross the host epithelial barrier through attachment to carbohydrate 
moieties of host cell glycoproteins, glycolipids such as sialic acid, and proteoglycans (280). 
Human noroviruses in addition to binding to histo-blood group antigens are also known to bind 
to porcine gastric mucin (PGM) (281). PGM has been used widely in studies to discriminate 
between infectious and non-infectious norovirus particles (282).  
The objectives of this research were (1) to evaluate the antiviral properties of blueberry 
proanthocyanidins (B-PAC) and commercial blueberry juice (BJ) against human norovirus 
surrogates, namely feline calicivirus (FCV-F9) and murine norovirus (MNV-1); hepatitis A virus 
and Aichi virus; (2) to determine the antiviral activity of BJ and B-PAC against these test viruses 
in model food systems and under simulated gastric conditions and (3) to understand the 
mechanism of action of B-PAC and BJ against the tested viruses. 
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Appendix A 
Table 1.1 General properties of common foodborne viruses 
 HNoV HAV Aichi virus Rotavirus HEV 
Family 
Genus 
Caliciviridae; 
Norovirus 
Picornaviridae 
Hepatovirus 
Picornaviridae; 
Kobuvirus 
Reoviridae; 
Enterovirus 
Hepevirus; 
Hepeviridae 
Genome  
(+) ssRNA, 
7.5 kb 
(+) ssRNA,  
7.5 kb 
(+) ssRNA,  
8.2 kb 
dsRNA,  
7.5 kb 
(+) ssRNA, 
7.3 kb 
Particle size 
(nm) 
27-38 27-32 27-30 30 27-34 
Envelope No No No No No 
Route  
of 
transmission 
Fecal oral  Fecal oral  Fecal oral  Fecal oral  Fecal oral 
Incubation 
period 
24-48 h 4 weeks 24-48 h 2-4 days 40 days 
Symptoms 
Diarrhea, 
nausea, 
vomiting, 
abdominal 
pain 
Malaise, dark 
urine, nausea, 
vomiting, 
jaundice 
Diarrhea, 
abdominal pain, 
nausea, vomiting 
Vomiting, 
diarrhea, 
dehydration, 
fever 
Jaundice, 
anorexia, 
Acute liver 
failure 
 
Vaccine Not available Available Not available Available Available 
*HNoV: human norovirus; HAV: hepatitis A virus; HEV: hepatitis E virus 
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Table 1.2 Human norovirus outbreaks 
Year Sample type Contamination source/Location Detection method Reference 
2014 Clinical Cruise ship Not known (8) 
2013 Not known 
Unknown source (tourists), Yellow 
stone national park 
Epidemiology 
CDC, 2013 
2012 Food Imported frozen raspberries Epidemiology (283) 
2011 Stool sample 
Pasta, raw vegetables/ French military 
unit 
RT PCR 
(284) 
2009 
Clinical, food, 
environmental 
Salad/German military base RT PCR 
(285) 
2009 Stool Water resort 
RT-qPCR, 
Epidemiology 
(286) 
2009 Clinical Cruise ship RT-qPCR (287) 
2008 Water Municipal drinking water/Sweden Epidemiology (288) 
2008 Clinical University dining hall 
Epidemiology; RT 
PCR 
(289) 
2003 
Food and 
clinical 
Oysters 
Epidemiology; RT 
PCR 
(290) 
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Table 1.3 Hepatitis A virus outbreaks 
Year Sample type 
Contamination 
source/Location 
Detection method Reference 
2013 Food 
Frozen berries in 
smoothies/ Nordic 
countries 
Epidemiology (291) 
2011 Food Sundried tomatoes Epidemiology (53) 
2011 Serum Sushi bar, Japan RT PCR (292) 
2009 Serum Sun dried tomatoes RT PCR (52) 
2009 Serum Well water 
Epidemiology, detection of anti-
IgM 
(293) 
2008 Serum/ stool Thai navy base Detection of anti-IgM, RT-PCR (294) 
2004 Clinical 
Orange Juice/ 
Egyptian restaurant 
RT PCR 
(295) 
2003 Serum Green onions Epidemiology, RT-PCR (54) 
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Table 1.4 Rotavirus and Hepatitis E virus outbreaks 
Virus Type Year Sample type 
Contamination 
source/Location 
Detection method Reference 
    Rotavirus 
2012 Clinical 
French Reunion 
island 
RT PCR 
(296) 
2011 Clinical 
Retirement 
communities 
EIA, RT PCR 
(297) 
2011 Clinical 
Intensive care 
unit/Brazil 
RT PCR 
(298) 
2007 Clinical 
Pediatric 
hospital/Mexico 
ELISA 
(299) 
1997 Stool, Serum Pediatric unit/Toys Epidemiology, EIA 
(300) 
 
Hepatitis  
E virus 
2011 Serum Italy 
RT PCR, Detection 
of IgG and IgM by 
immunoassay 
(301) 
2011 Food Shellfish/England RT PCR 
(302) 
2007 Blood Uganda RT PCR 
(303) 
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Table 1.5 Effect of grape seed extract (GSE) and its components against viruses 
Type of 
bioactive 
Concentration Virus Reduction Reference 
     GSE 
1 mg/ml 
FCV-F9 4.61 log PFU/ml 
(197) MNV-1 1.73 log PFU/ml 
HAV 3.2 log PFU/ml 
0.2 mg/ml MNV-1 3 log PFU/ml (144) 
 
Resveratrol 
 
40 μg/mL 
Influenza 
virus 
Complete 
inhibition 
(201) 
 
20 uM Polyomavirus 
Complete 
inhibition 
(202) 
10μM 
Human 
immunodeficiency 
virus – 1 
20-30% 
reduction in 
replication 
(304) 
                         *FCV-F9: feline calicivirus; MNV-1: murine norovirus; HAV: hepatitis A virus  
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Table 1.6 Antiviral activity of blueberry polyphenols 
Type of bioactive Concentration Virus Effect Reference 
Blueberry 
proanthocyanidin 
5.47 µg/ml Hepatitis C virus Inhibition of  
subgenome 
expression 
(156) 
Tannins  0.03-0.1 µg/ml Herpes simplex 
virus 
Inhibition of 
adsorption 
to its host 
(157) 
Blueberry juice 4
0
C after 1 day FCV-F9 Reduction to 
undetectable 
levels 
(2) 
*FCV-F9: feline calicivirus 
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Table 1.7 Antiviral properties of additional fruit extracts 
Type of bioactive Concentration Virus Effect Reference 
Cranberry juice   30 min FCV-F9 Reduction to undetectable 
levels  
(250) 
Cranberry juice 30% Simian 
rotavirus SA-
11 
Reduction to undetectable 
levels 
(101) 
CPAC 0.15-0.3mg/ml FCV-F9 Reduction to undetectable 
levels  
(250) 
Black raspberry 
juice 
6% MNV-1 99% reduction (253) 
Blackberries 56 μg/mL HSV-1 99% reduction (255) 
Pomegranate 
polyphenols 
800 μg/ml 
5 min at room 
temperature 
Human 
influenza 
viruses 
(H1N1, 
H3N2, and 
H5N1) 
3 log PFU/ml reduction (239) 
Pomegranate juice Room 
temperature  
1h 
FCV-F9 
 
MNV-1 
 
MS2 
 
 2.56 log PFU/ml 
 
1.32 log PFU/ml 
 
0.32 log PFU/ml 
 
(241) 
*FCV-F9: feline calicivirus; MNV-1: murine norovirus; HAV: hepatitis A virus  
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Figure 1.1 Representative structures of flavan-3-ol monomers and their dimers (B-type PACs). 
When R1= OH and R2= H, the monomer is (-)-epicatechin. When R1= H and R2= OH, then the 
monomer is (+)-catechin. (Adapted from Hammerstone et al., 2000). 
 
 
 
 
 
 
 
 
Figure 1.2. A-type and B-type PACs (Adapted from Blumberg et al., 2013) 
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Chapter 2 Reduction of enteric viruses by blueberry juice and 
blueberry proanthocyanidins 
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Blueberry and blueberry extracts are known for their health benefits and antimicrobial properties. 
Natural therapeutic or preventive options to decrease the incidences of foodborne viral illnesses 
are becoming popular and being researched. This study aimed to determine the antiviral effects 
of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) against the infectivity of 
hepatitis A virus (HAV), Aichi virus (AiV) and human norovirus surrogates (feline calicivirus 
(FCV-F9) and murine norovirus (MNV-1)) at 37ºC over 24-h using standard plaque assays. 
Viruses at ~5 log PFU/ml were mixed with equal volumes of BJ (pH 2.8), neutralized BJ (pH 
7.0), B-PAC (1, 2, 4, and 10 mg/ml), malic acid (pH 3.0), or phosphate buffered saline (pH 7.2) 
and incubated over 24-h at 37
o
C. Each experiment was carried out in duplicate and replicated 
thrice. FCV-F9 titers were found to be reduced to undetectable levels with 1 and 2 mg/ml B-PAC 
after 5 min, after 1 h with 0.5 mg/ml B-PAC, and with BJ after 3-h. MNV-1 titers were reduced 
to undetectable levels after 3-h with 1, 2, and 5 mg/ml B-PAC and after 6-h with BJ. HAV titers 
were reduced to undetectable levels after 30 min with 2 and 5 mg/ml B-PAC, after 3-h with 1 
mg/ml B-PAC, and by ~2 log PFU/ml with BJ after 24-h. B-PAC at 5 mg/ml reduced AiV titers 
to undetectable levels after 3 h, while BJ caused reductions to undetectable levels after 24 h. B-
PAC shows potential to control enteric viruses in a dose and time-dependent manner, although 
further in vitro studies in model food systems and in vivo studies using animal models are 
warranted.  
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Introduction 
 
Foodborne pathogens in the United States lead to an estimated 9.4 million illnesses, 55,961 
hospitalizations, and 1,351 deaths of which foodborne viruses such as human norovirus alone are 
responsible for 5.5 million illnesses (58%) per year (1). Recent reports indicate that this number 
has risen to 21 million illnesses per year (2). Human norovirus and hepatitis A virus have been 
linked to several foodborne and waterborne outbreaks in the US as well as worldwide (3). Aichi 
virus is an emerging pathogen is transmitted via the fecal-oral route and shed in the feces and 
hence seafood like shellfish from sewage-contaminated water can be a source of contamination 
(4, 5). AiV-related gastrointestinal cases have been reported all over the world including in 
Asian, African, European and South American countries (6-11). These foodborne viruses are 
now recognized worldwide as public health concerns and therefore effective natural alternatives 
to control their spread are being researched. This is important for the treatment or potential 
alleviation of illness symptoms and prevention of disease in the current absence of available 
vaccines for human noroviruses. Recently, the antiviral effects of grape seed extract (GSE) 
against human norovirus surrogates, FCV-F9 and MNV-1, and hepatitis A virus (HAV) at 37ºC 
for 2 h were reported (12). Cranberry juice and its proanthocyanidins were also reported to cause 
reduction of human norovirus surrogates (13). 
Blueberries also contain structurally related polyphenols, including anthocyanins, 
flavonoids, and proanthocyanidins (PAC), sometimes referred to as condensed tannins (14). 
Blueberries and its polyphenols have been evaluated for their potential health benefits including 
their anticarcinogenic, neuroprotective, cardioprotective, antibacterial, and antiviral properties 
(15-19). Blueberry extracts at a concentration of 0.25% are known to have antimicrobial activity 
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and are reported to cause 50.5% inhibition of Helicobacter pylori, the bacterium associated with 
ulcers (20). Water and ethanol extracts of blueberries at 24 ppm were reported to cause a 5.90 
log CFU/ml reduction of Listeria monocytogenes after 24 h at 37ºC in vitro (21). Recently, 
monomeric phenolics acids (0.4g/L gallic acid) from blueberries were shown to reduce 
Escherichia coli O157:H7 by 5 log CFU/ml along with cell-membrane damage after 24 h at37ºC 
in vitro (22). Additionally, using the HCV replicon cell system, the methanol extract fraction of 
blueberry leaves (0.112–2200 μg/ml) was shown to inhibit hepatitis C (HCV) virus subgenomic 
expression after 72h at 37ºC (23). Hydrolysable and galloylated tannin (0.03–0.1 μg/ml) was 
reported to inhibit the adsorption of herpes simplex virus to its hosts, African green monkey 
kidney cells and human adenocarcinoma cells at 37
o
C (24). Human norovirus surrogates such as 
feline calicivirus (FCV-F9) and murine norovirus (MNV-1) have been studied for survival in 
commercial blueberry juice (BJ) at 4ºC, where FCV-F9 was undetectable after 24 h from initial 5 
log PFU/ml, whereas MNV-1 showed minimal reduction after 21 days at 4ºC (25). 
Blueberries and blueberry phenols could potentially be used as part of a diet to prevent or 
treat human norovirus related gastroenteritis. Therefore, the objective of this study was to 
determine the effect of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) on the 
infectivity of hepatitis A virus (HAV), Aichi virus (AiV) and human norovirus surrogates (FCV-
F9 and MNV-1) at 37ºC over a period of up to 24 h using standardized plaque assays. 
Materials and Methods 
 
Viruses and cell lines 
Feline calicivirus (FCV-F9) and host Crandell Reese Feline Kidney (CRFK) cells were 
purchased from ATCC (ATCC identifying number VR-2057; Manassas, VA). Murine norovirus 
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(MNV-1) was kindly gifted by Dr. Skip Virgin (Washington Univ., St. Louis, MO) and RAW 
264.7 cells were obtained from the University of Tennessee at Knoxville.Hepatitis A virus 
(HAV; strain HM175) and fetal rhesus monkey kidney (FRhK4) cells were provided by our 
collaborator, Dr. Kalmia Kniel (University of Delaware). Aichi virus (AiV) was kindly provided 
by Dr. David Kingsley (USDA ARS, Delaware) and propagated using Vero host cells. Host cell 
lines were maintained using Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM-F12; 
HyClone Laboratories, Logan, UT) containing 2 or 10% heat-inactivated fetal bovine serum 
(FBS, HyClone Laboratories) and 1x Anti-Anti (Antibiotic-Antimycotic, Invitrogen, Grand 
Island, NY) at 37ºC in an atmosphere containing 5% CO2.   
Propagation of viruses 
 
To prepare stocks of FCV-F9, MNV-1, AiV and HAV, respective host cell lines at 90% 
confluency were inoculated with each virus and incubated for 2, 6, 3 and 8 days, respectively 
under 5% CO2 at 37ºC. The viruses were harvested by 1 to 3 freeze thaw cycles followed by 
centrifugation at 5,000 xg for 10 min. The supernatant was filtered through a 0.2-m filter, 
aliquoted, stored at -80ºC until further use and titers of the recovered viral stocks were 
determined using standard reported plaque assays (13, 26). 
Propagation of viruses 
 
To prepare stocks of FCV-F9, MNV-1, AiV and HAV respective host cell lines at 90% 
confluency were inoculated with each virus and incubated for 2, 6, 3 and 8 days, respectively 
under 5% CO2 at 37ºC. The viruses were harvested by 1 to 3 freeze thaw cycles followed by 
centrifugation at 5,000 xg for 10 min. The supernatant was filtered through a 0.2-m filter, 
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aliquoted, stored at -80ºC until further use and titers of the recovered viral stocks were 
determined using standard reported plaque assays (13, 26). 
Isolation of PAC from blueberries 
 
Proanthocyanidins were isolated from frozen highbush blueberry fruit (Vaccinium corymbosum 
L.) using solid-phase chromatography according to a well-established method for 
proanthocyanidin isolation (27). Briefly, blueberry fruit was homogenized with 70% aqueous 
acetone, filtered and the pulp discarded. The collected extract was concentrated under reduced 
pressure to remove acetone. The blueberry extract was suspended in water, applied to a 
preconditioned C-18 solid phase chromatography column and washed with water to remove 
sugars, followed by acidified aqueous methanol to remove acids. The fats and waxes retained on 
the C-18 sorbent were discarded. The polyphenolic fraction containing anthocyanins, flavonol 
glycosides and proanthocyanidins (confirmed using reverse phase HPLC with diode array 
detection) was eluted with 100% methanol and dried under reduced pressure. This fraction was 
suspended in 50% EtOH, applied to a pre-conditioned Sephadex LH-20 column which was 
washed with 50% EtOH to remove low molecular weight anthocyanins and flavonol glycosides. 
Proanthocyanidins adsorbed to the LH-20 were eluted from the column with 70% aqueous 
acetone, and monitored using diode array detection at 280 nm. The absence of absorption at 360 
nm and 450 nm confirmed that anthocyanins and flavonol glycosides were removed. Acetone 
was removed under reduced pressure and the resulting purified proanthocyanidin extract freeze-
dried.  Electrospray mass spectrometry, 
13
C NMR, matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry and acid catalyzed degradation with phloroglucinol have all 
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been utilized to confirm the purity of proanthocyanidins present in the extract obtained using this 
method (27). 
Effect of BJ and B-PAC on host cells lines 
 
Cytopathic effects of B-PAC, BJ (pH 2.8) and NBJ (neutralized blueberry juice; pH 7.0) 
treatments on the host cell lines were also determined. The maximum concentration of B-PAC 
used in the viral treatment and assays was 5 mg/ml. However, the host cell lines were exposed to 
only a 20-fold dilution of the treatment after neutralization/stopping of the treatment. Thus, each 
individual host cell lines on confluent 6-well plates were exposed to B-PAC at 0.5 mg/ml and BJ 
and NBJ for 2 h at 37
o
C and observed under optical microscope (Fisher Scientific; 120 VAC) to 
determine visible cytopathic effects or changes. 
Antiviral effect of BJ and B-PAC 
 
Commercial blueberry juice (cocktail with grape and apple juice; preservatives listed include 
malic acid and sodium citrate) was purchased from local grocery stores and B-PAC was 
fractionated by Dr. Amy Howell (Marucci Center for Blueberry and Cranberry Research, 
Rutgers University, Chatsworth, NJ) and kindly gifted for this work. B-PAC was dissolved in 
10% ethanol and filter-sterilized through 0.2-micron filters to obtain a stock of 10 mg/ml. Equal 
volumes of each virus at a titer of ~5 log PFU/ml was individually mixed with BJ (pH 2.8), B-
PAC (1, 2, 4, and 10 mg/ml), malic acid (pH 3.0), neutralized BJ (pH 7 using 4 M sodium 
hydroxide, NaOH), 10% ethanol or phosphate buffered saline (PBS; 7.2 as control) and 
incubated at 37ºC for 5 (0.08 h), 15 (0.25h), 30 (0.5h), 60 (1h), 120 (2 h), 180 (3 h), 360 min (6 
h) or 24h. Treatments were stopped using initial serial dilutions of the treated virus with cell-
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culture media containing 10% heat-inactivated FBS, followed by dilutions in cell-culture media 
containing 2% FBS. The infectivity of viruses was evaluated using standard plaque assays as 
described before (13). Each experiment was replicated thrice and assayed in duplicate. 
Statistical analysis 
 
Statistical analysis was carried out using ANOVA with SAS software (version 9.3, SAS Institute, 
Cary, NC, USA) and Tukey’s test with data obtained from the three replications for each 
individual virus as described in previous studies (12, 28). 
Results 
 
Effect of B-PAC and BJ on host cells lines 
 
B-PAC at a concentration of 0.5 mg/ml was not found to be cytotoxic to the tested host cell lines. 
Undiluted BJ when added directly to the host cells had some minor effects after 2h. However, 
neutralized BJ (NBJ) did not show any morphological visual changes in the host cells and was 
used further in the time of addition experiments. In the experiment involving treatment of viruses 
with B-PAC, the cells are exposed to a maximum of 20-fold diluted B-PAC and hence the host 
cells do not show cytopathic effects.  
Reduction of viral titers by B-PAC and BJ 
 
All four tested viruses were found to be susceptible to the B-PAC treatment carried out at 37
o
C. 
FCV-F9 from initial titers of ~5 log PFU/ml were reduced to undetectable levels (to <10
2
PFU/ml 
per detection limit of the assay) after 5 min with 1, 2, and 5 mg/ml B-PAC, and to undetectable 
levels (> 3 log PFU/ml reduction) after 60 min with 0.5 mg/ml B-PAC. After 5 min, lower 
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concentration of 0.5 mg/ml B-PAC reduced FCV-F9 titers by only 1.33±0.03 log PFU/ml and 
after 30 min by 2.19±0.22 log PFU/ml (Table 2.1). MNV-1 was less sensitive to B-PAC 
treatments compared to FCV-F9, where MNV-1 at initial titers of~5 log PFU/ml were reduced to 
undetectable levels only after 3 h with 1, 2, and 5 mg/ml of B-PAC. Lower concentration of 0.5 
mg/ml B-PAC caused MNV-1 reductions of 1.47±0.05 log PFU/ml after 3 h and caused slightly 
higher reductions of 1.83±0.10 log PFU/ml after 6 h. (Table 2.2). HAV titers were reduced to 
undetectable levels after 30 min with 2 and 5 mg/ml B-PAC, whereas 1 mg/ml B-PAC reduced 
HAV titers by 1.71±0.21 log PFU/ml after 30 min and to undetectable levels only after 3 h 
(Table 2.3). Lower concentration of 0.5 mg/ml B-PAC caused mere reductions of 0.55±0.04, 
0.79±0.06 and 0.69±0.04 log PFU/ml in HAV titers after 1, 3 and 6 h at 37
o
C. B-PAC (1 mg/ml) 
at 37
o
C was shown to be effective in reducing AiV titers by 0.48±0.01, 1.50±0.02, 1.84±0.25, 
1.45±0.35 and 2.13±0.06 PFU/ml after 0.5, 1, 3, 6 and 24 h, respectively. Increased 
concentration caused higher titer reduction where 2 mg/ml B-PAC caused reductions of 
0.93±0.10, 1.63±0.22, and 1.82±0.07 log PFU/ml after 0.5, 1, and 3 h respectively and to 
undetectable levels after 6 and 24 h. The highest tested concentration of B-PAC at 5 mg/ml was 
found to be the most effective that caused reductions of 1.39 ± 0.04 and 1.76 ± 0.54 log PFU/ml 
after 0.5 and 1 h, respectively, and to undetectable levels after 3 h (Table 2.4). 
Commercial BJ did not have a prominent effect on the viral titers after shorter contact times. 
Among the three tested viruses, FCV-F9 was the most sensitive, where BJ reduced FCV-F9 titers 
to undetectable levels after 3 h (Table 2.5). However, BJ did not have a significant effect on 
MNV-1 and HAV after 3 h. MNV-1 titers were reduced to undetectable levels only after 24 h 
with BJ while HAV was reduced by 1.86±0.05 log PFU/ml after 24 h with BJ (Table 2.6 and 
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2.7). Both, malic acid (pH 3.0, control) and neutralized BJ (pH 7.0) did not have any significant 
effect in reducing the titers of all FCV-F9, MNV-1 and HAV, compared to non-neutralized BJ 
(pH 2.8) that showed ~2-3 log PFU/ml reduction after 24 h. Thus, the reduction cannot be 
attributed solely to pH effects, indicating that BJ bioactives contributed to the reduction. 
Treatment of AiV at ~5 log PFU/ml with BJ at 37
o
C resulted in titer reductions of 0.17±0.06, 
1.27±0.01 and 1.73±0.23, log PFU/ml after 1, 3 and 6 h, and to undetectable levels after 24 h. 
Neutralized BJ (pH 7.0) showed 0.07±0.11, 0.0±0.0, 0.06±0.07 and 0.23±0.11 log PFU/ml after 
1, 3, 6 and 24 h. Malic acid (pH 3.0, acid control) was shown to have minimal effects on virus 
infectivity over time though to a much lesser extent than BJ within 6 h, causing titer reductions 
of 0.08±0.0, 0.25±0.06 and 0.84±0.23 log PFU/ml after 1, 3 and 6 h and to undetectable levels 
after 24 h, indicating that low pH also contributes to the antiviral effect of BJ on AiV over 
extended time (Table 2.8). 
Discussion 
 
B-PAC and BJ were found to be effective in reducing the titers of all the three tested viruses. B-
PAC showed dose and time-dependence effects against the four tested viruses where higher 
concentration and longer time had the greatest antiviral effects especially for MNV-1 and HAV. 
Between the two tested human norovirus surrogates, FCV-F9 was found to be the more sensitive 
surrogate to treatments than MNV-1. This is not surprising as similar patterns are reported when 
comparing FCV-F9 and MNV-1 using chemical treatments and plant-derived extracts such as 
trisodium phosphate (TSP) and GSE (12, 29). Previous studies have also shown that MNV-1 is 
the sturdier of the surrogates when exposed to extreme heat and pH (30). HAV was found to be 
moderately sensitive to B-PAC treatment where complete reduction was achieved with 2 and 
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5mg/ml B-PAC after 30 min. HAV is known to be highly stable in the environment and can 
retain infectivity for long periods of time, and can survive in mineral water stored at room 
temperature up to 300 days (31). It is also resistant to extreme acidic pH, where it was shown to 
survive in acidic marinade at pH 3.75 over 4 weeks and even at pH 1.0 even after 5 h (32, 33). 
Thus, the antiviral effect of B-PAC against HAV is quite noteworthy. 
Bioactive compounds such as gallic acid, epicatechin, tannins, and proanthocyanidins 
found in berry fruits are known to be effective antimicrobial agents (34-36). Polyphenols from 
fruits such as pomegranate, cranberry, grapes (seed), and other plant extracts have been shown to 
possess antiviral properties including against human norovirus surrogates (13, 37, 38). FCV-F9 
was found to be undetectable after 1 day in BJ as well as in orange and 
pomegranate juice blend at 4°C (25, 39). MNV-1 was reported to be completely reduced after 7 
days in the orange and pomegranate juice blend, however only 1 log PFU/ml reduction of MNV-
1 was observed in BJ at 4ºC after 14 days (25, 39). Black raspberry juice at 6% was found to 
reduce MNV-1 plaque formation by 99% after 1 h at 37ºC (38). However in the current study, BJ 
treatment needed longer contact time to achieve similar reduction, which could be attributed to 
the fact that black raspberry juice was freshly made by hand, and might have higher 
concentration of polyphenols, whereas commercially available BJ was used in our study. Grape 
seed extract (GSE), cranberry proanthocyanidins (CPAC) and pomegranate polyphenols (PP) 
have been reported for their antiviral properties against FCV-F9 and MNV-1 (12, 13, 37).FCV-
F9 and MNV-1 were reduced to undetectable levels and by 2.95 log PFU/ml, respectively with 
0.6 mg/ml CPAC after 1 h at RT (40).GSE at 0.5 and 1 mg/ml reducedFCV-F9 titers to 
undetectable levels within 15 min at 37
o
C and RT, and MNV-1 titers were reduced by ~1 log 
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PFU/ml after 1 h at 37
o
C and RT (12). FCV-F9 and MNV-1 were also sensitive to PP treatments 
at RT, where PP at 2 mg/ml decreased FCV-F9 titers to undetectable levels after 30 min and 
MNV-1 titers were reduced by 0.9 log PFU/ml after 60 min (37). In this study, B-PAC at 2 
mg/ml reduced FCV-F9 titer to undetectable levels within 5 min and MNV-1 by 1.65 log 
PFU/ml after 60 min at 37
o
C.When comparing these polyphenol extracts for their antiviral 
activity against FCV-F9 and MNV-1, their effect follows the order of CPAC>GSE>B-PAC>PP. 
 In comparison to human norovirus surrogates, fewer studies are reported in literature on 
the antiviral effects of natural extracts against HAV. In a previous study, GSE at 1mg/ml was 
shown to reduce HAV titers from initial 5 log PFU/ml by 2.89 log PFU/ml after 2h at 37
o
C (12). 
HAV titers at initial 5.74 log PFU/ml were also shown to be decreased by 0.66 log PFU/ml when 
treated with 10 μg/mL Korean red ginseng, and decreased by 0.37 log PFU/ml when treated with 
10 μg/mL purified ginsenoside extract after 24 h at 37oC (41). B-PAC treatment, although at a 
higher concentration, was found to be effective in reducing HAV titers where 2mg/ml B-PAC 
caused reduction to undetectable levels within 30 min at 37
o
C.   
A few other studies have reported AiV to be resistant to inactivation treatments. Essential 
oil extracts from Origanu macutidens were shown to be ineffective in inhibiting AiV replication 
in vivo (42).  AiV remained fully infectious after a 5-min treatment at 600 MPa in MEM 
(minimum essential medium) supplemented with 2 and 10% FBS, respectively (43). AiV 
reductions on lettuce, green onions, and strawberries at 240 mW s/cm2 were 4.59, 2.49, and 1.87 
log TCID50 /ml, respectively (26). This suggests that AiV is quite resilient to physical 
inactivation treatments. In this study B-PAC treatments were more effective in comparison to 
most of the reported disinfectant treatments. AiV reductions of 1.39 and 1.76 log PFU/ml were 
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seen after 0.5 and 1 h with 5 mg/ml B-PAC and reduction to undetectable levels was obtained 
after 3 h with 5mg/ml B-PAC. 
Neutralized BJ did not have any significant effect in reducing the viral titers. As PACs 
are known to be stable under acidic conditions, increasing the pH can change the structure of 
PAC, thereby potentially changing its bioactivity. Moreover, the malic acid (pH 3.0) pH control 
by itself alone also did not significantly contribute to the titer reduction. It could be speculated 
that both the bioactive components of BJ and the acidic pH together contributed towards the 
antiviral activity. Bioactive components of BJ were not individually analysed for antiviral 
activity in this study. 
It is well recognized that effectiveness of antimicrobials can decrease in the presence 
complex food matrices where components of foods such as lipids, proteins or other acidic or 
alkaline conditions may interfere with the antiviral properties.  Hence, along with studying the 
effect of these blueberry polyphenols on the viral infectivity in vitro, it is also crucial to further 
investigate their effectiveness in presence of food matrices and under simulated gastric 
conditions for use as potential antiviral therapeutics. Some studies have been conducted with 
plant extracts (hibiscus) in milk and apple juice against E. coli and Staphylococcus aureus where 
antimicrobial activity was shown to reduce in foods with higher lipid and protein load (44). A 
similar study was carried out using black tea and tea in milk against oral pathogen Streptococcus 
mutans, where reduced antimicrobial activity of tea made in milk was reported (45). This 
decrease in activity was attributed to complex formation of milk proteins and tea polyphenols 
and subsequent decrease in the bioavailability of polyphenols (45). Therefore, future studies are 
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aimed to determine the antiviral effects of B-PAC in food systems such as milk (high in lipids) 
and apple juice, and also simulated gastric conditions. 
Acknowledgements 
The support provided by OceanSpray Cranberries Inc., and the University of Tennessee-Institute 
of Agriculture (TEN #00391) to carry out this work is gratefully acknowledged. The authors also 
acknowledge Dr. Dunlap at UT-Advanced Microscopy Center for his assistance with the TEM 
observation.  
91 
 
References 
 
1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, 
Griffin PM. 2011. Foodborne illness acquired in the United States--major pathogens. 
Emerging infectious diseases 17:7-15. 
2. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, Vinje J, Parashar UD. 
2013. Norovirus disease in the United States. Emerging infectious diseases 19:1198-
1205. 
3. CDC 2014, posting date. Center for Disease Control and Prevention [Online.] 
4. Reuter G, Boldizsar A, Papp G, Pankovics P. 2009. Detection of Aichi virus shedding 
in a child with enteric and extraintestinal symptoms in Hungary. Archives of virology 
154:1529-1532. 
5. Yamashita T, Kobayashi S, Sakae K, Nakata S, Chiba S, Ishihara Y, Isomura S. 
1991. Isolation of cytopathic small round viruses with BS-C-1 cells from patients with 
gastroenteritis. The Journal of infectious diseases 164:954-957. 
6. Goyer M, Aho LS, Bour JB, Ambert-Balay K, Pothier P. 2008. Seroprevalence 
distribution of Aichi virus among a French population in 2006-2007. Archives of 
virology 153:1171-1174. 
7. Kaikkonen S, Rasanen S, Ramet M, Vesikari T. 2010. Aichi virus infection in children 
with acute gastroenteritis in Finland. Epidemiology and infection 138:1166-1171. 
8. Ribes JM, Montava R, Tellez-Castillo CJ, Fernandez-Jimenez M, Buesa J. 2010. 
Seroprevalence of Aichi virus in a Spanish population from 2007 to 2008. Clinical and 
vaccine immunology : CVI 17:545-549. 
9. Jonsson N, Wahlstrom K, Svensson L, Serrander L, Lindberg AM. 2012. Aichi virus 
infection in elderly people in Sweden. Archives of virology 157:1365-1369. 
10. Sdiri-Loulizi K, Gharbi-Khelifi H, de Rougemont A, Chouchane S, Sakly N, 
Ambert-Balay K, Hassine M, Guediche MN, Aouni M, Pothier P. 2008. Acute 
infantile gastroenteritis associated with human enteric viruses in Tunisia. Journal of 
clinical microbiology 46:1349-1355. 
11. Oh DY, Silva PA, Hauroeder B, Diedrich S, Cardoso DD, Schreier E. 2006. 
Molecular characterization of the first Aichi viruses isolated in Europe and in South 
America. Archives of virology 151:1199-1206. 
12. Su X, D'Souza DH. 2011. Grape seed extract for control of human enteric viruses. 
Applied and environmental microbiology 77:3982-3987. 
13. Su X, Howell AB, D'Souza DH. 2010. The effect of cranberry juice and cranberry 
proanthocyanidins on the infectivity of human enteric viral surrogates. Food 
microbiology 27:535-540. 
14. Huang WY, Zhang HC, Liu WX, Li CY. 2012. Survey of antioxidant capacity and 
phenolic composition of blueberry, blackberry, and strawberry in Nanjing. Journal of 
Zhejiang University. Science. B 13:94-102. 
15. Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D. 2007. Berry 
anthocyanins as novel antioxidants in human health and disease prevention. Molecular 
nutrition & food research 51:675-683. 
92 
 
16. Heinonen M. 2007. Antioxidant activity and antimicrobial effect of berry phenolics--a 
Finnish perspective. Molecular nutrition & food research 51:684-691. 
17. Hou DX. 2003. Potential mechanisms of cancer chemoprevention by anthocyanins. 
Current molecular medicine 3:149-159. 
18. Basu A, Du M, Leyva MJ, Sanchez K, Betts NM, Wu M, Aston CE, Lyons TJ. 2010. 
Blueberries decrease cardiovascular risk factors in obese men and women with metabolic 
syndrome. The Journal of nutrition 140:1582-1587. 
19. Elks CM, Reed SD, Mariappan N, Shukitt-Hale B, Joseph JA, Ingram DK, Francis 
J. 2011. A blueberry-enriched diet attenuates nephropathy in a rat model of hypertension 
via reduction in oxidative stress. PloS one 6:e24028. 
20. Chatterjee A, Yasmin T, Bagchi D, Stohs SJ. 2004. Inhibition of Helicobacter pylori in 
vitro by various berry extracts, with enhanced susceptibility to clarithromycin. Molecular 
and cellular biochemistry 265:19-26. 
21. Park YJ, Biswas R, Phillips RD, Chen J. 2011. Antibacterial activities of blueberry and 
muscadine phenolic extracts. Journal of food science 76:M101-105. 
22. Lacombe A, Tadepalli S, Hwang CA, Wu VC. 2013. Phytochemicals in Lowbush Wild 
Blueberry Inactivate Escherichia coli O157:H7 by Damaging Its Cell Membrane. 
Foodborne pathogens and disease 10:944-950. 
23. Takeshita M, Ishida Y, Akamatsu E, Ohmori Y, Sudoh M, Uto H, Tsubouchi H, 
Kataoka H. 2009. Proanthocyanidin from blueberry leaves suppresses expression of 
subgenomic hepatitis C virus RNA. The Journal of biological chemistry 284:21165-
21176. 
24. Fukuchi K, Sakagami H, Okuda T, Hatano T, Tanuma S, Kitajima K, Inoue Y, 
Inoue S, Ichikawa S, Nonoyama M, et al. 1989. Inhibition of herpes simplex virus 
infection by tannins and related compounds. Antiviral research 11:285-297. 
25. Horm KM, Davidson PM, Harte FM, D'Souza DH. 2012. Survival and inactivation of 
human norovirus surrogates in blueberry juice by high-pressure homogenization. 
Foodborne pathogens and disease 9:974-979. 
26. Fino VR, Kniel KE. 2008. UV light inactivation of hepatitis A virus, Aichi virus, and 
feline calicivirus on strawberries, green onions, and lettuce. Journal of food protection 
71:908-913. 
27. Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. 
2005. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion 
activity. Phytochemistry 66:2281-2291. 
28. Su X, D'Souza DH. 2013. Grape seed extract for foodborne virus reduction on produce. 
Food microbiology 34:1-6. 
29. D'Souza DH, Su X. 2010. Efficacy of chemical treatments against murine norovirus, 
feline calicivirus, and MS2 bacteriophage. Foodborne pathogens and disease 7:319-326. 
30. Cannon JL, Papafragkou E, Park GW, Osborne J, Jaykus LA, Vinje J. 2006. 
Surrogates for the study of norovirus stability and inactivation in the environment: aA 
comparison of murine norovirus and feline calicivirus. Journal of food protection 
69:2761-2765. 
93 
 
31. Biziagos E, Passagot J, Crance JM, Deloince R. 1988. Long-term survival of hepatitis 
A virus and poliovirus type 1 in mineral water. Applied and environmental microbiology 
54:2705-2710. 
32. Hewitt J, Greening GE. 2004. Survival and persistence of norovirus, hepatitis A virus, 
and feline calicivirus in marinated mussels. Journal of food protection 67:1743-1750. 
33. Scholz E, Heinricy U, Flehmig B. 1989. Acid stability of hepatitis A virus. The Journal 
of general virology 70 ( Pt 9):2481-2485. 
34. Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. 2013. 
Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients 
5:3779-3827. 
35. Bahadoran Z, Mirmiran P, Azizi F. 2013. Dietary polyphenols as potential 
nutraceuticals in management of diabetes: a review. Journal of diabetes and metabolic 
disorders 12:43. 
36. Li D, Baert L, Uyttendaele M. 2013. Inactivation of food-borne viruses using natural 
biochemical substances. Food microbiology 35:1-9. 
37. Su X, Sangster MY, D'Souza DH. 2010. In vitro effects of pomegranate juice and 
pomegranate polyphenols on foodborne viral surrogates. Foodborne pathogens and 
disease 7:1473-1479. 
38. Oh M, Bae SY, Lee JH, Cho KJ, Kim KH, Chung MS. 2012. Antiviral effects of black 
raspberry (Rubus coreanus) juice on foodborne viral surrogates. Foodborne pathogens 
and disease 9:915-921. 
39. Horm KM, D'Souza DH. 2011. Survival of human norovirus surrogates in milk, orange, 
and pomegranate juice, and juice blends at refrigeration (4 degrees C). Food 
microbiology 28:1054-1061. 
40. Su X, Howell AB, D'Souza DH. 2010. Antiviral effects of cranberry juice and cranberry 
proanthocyanidins on foodborne viral surrogates--a time dependence study in vitro. Food 
microbiology 27:985-991. 
41. Lee MH, Lee BH, Lee S, Choi C. 2013. Reduction of hepatitis A virus on FRhK-4 cells 
treated with Korean red ginseng extract and ginsenosides. Journal of food science 
78:M1412-1415. 
42. Sokmen M, Serkedjieva J, Daferera D, Gulluce M, Polissiou M, Tepe B, Akpulat 
HA, Sahin F, Sokmen A. 2004. In vitro antioxidant, antimicrobial, and antiviral 
activities of the essential oil and various extracts from herbal parts and callus cultures of 
Origanum acutidens. Journal of agricultural and food chemistry 52:3309-3312. 
43. Kingsley DH, Chen H, Hoover DG. 2004. Inactivation of selected picornaviruses by 
high hydrostatic pressure. Virus research 102:221-224. 
44. Higginbotham KL, Burris KP, Zivanovic S, Davidson PM, Stewart CN, Jr. 2014. 
Antimicrobial activity of Hibiscus sabdariffa aqueous extracts against Escherichia coli 
O157:H7 and Staphylococcus aureus in a microbiological medium and milk of various fat 
concentrations. Journal of food protection 77:262-268. 
45. A.A. Abd Allah MII, S.M. Abd Allah, M.A. Amin. 2012. Antimicrobial Effect of Tea 
and Tea with Milk Beverages on Oral Streptococcus mutans and Lactobacilli. World 
Applied Sciences Journal 19:1327-1334. 
  
94 
 
Appendix B 
Table 2.1 Effect of 0.5 to 5 mg/ml blueberry proanthocyanidins (B-PAC) on FCV-F9 at ~ 5 log PFU/ml at 37
o
C over 2 h. 
 Recovered titer (Log PFU/ml) 
Time 
(Min) 
PBS Ethanol 
(10%) 
B-PAC 
(0.5 mg/ml) 
B-PAC 
(1 mg/ml) 
B-PAC 
(2 mg/ml) 
B-PAC 
(5 mg/ml) 
5 4.87 ± 0.07
A
 4.76 ± 0.05
A
 3.54 ± 0.10
B
 0
D
 0
D
 0
D
 
30 4.83 ± 0.05
A
 4.77 ± 0.06
A
 2.64 ± 0.27
C
 0
D
 0
D
 0
D
 
60 5.03 ± 0.06
A
 4.73 ± 0.06
A
 0
D
 0
D
 0
D
 0
D
 
120 5.03± 0.06
A
 4.99± 0.06
A
 0
D
 0
D
 0
D
 0
D
 
                A, B, C, D
 Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
 
 
 
 
Table 2.2 Effect of 0.5 to 5 mg/ml blueberry proanthocyanidins (B-PAC) on MNV-1 at ~ 5 log PFU/ml at 37
o
C over 6 h. 
 Recovered titer (Log PFU/ml)  
Time 
(Min) 
PBS 
Ethanol 
(10%) 
B-PAC 
(0.5 mg/ml) 
B-PAC 
(1 mg/ml) 
B-PAC 
(2 mg/ml) 
B-PAC 
(5 mg/ml) 
30 4.89 ± 0.08
A
 4.56 ± 0.08
A
 3.80 ±0.06
AB
 3.71±0.05
BC
 3.43±0.09
BC
 3.28 ± 0.22
BC
 
60 4.84 ± 0.10
A
 4.82 ± 0.08
A
 3.67 ± 0.13
B
 3.49±0.08
BC
 3.19 ±0.19
C
 2.78±0.28
C
 
120 4.76 ± 0.01
A
 4.56 ± 0.08
A
 3.70 ± 0.13
B
 3.46±0.06
BC
 3.17 ±0.12
C
 2.76±0.09
C
 
180 4.75 ± 0.07
A
 4.75 ± 0.07
A
 3.28 ± 0.12
B
 0
D
 0
D
 0
D
 
360 4.63 ± 0.17
A
 4.61 ± 0.07
A
 2.80 ± 0.07
C
 0
D
 0
D
 0
D
 
A, B, C, D
 Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
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Table 2.3 Effect of 0.5 to 5 mg/ml blueberry proanthocyanidins (B-PAC) on HAV at ~ 5 log PFU/ml at 37
o
C over 3 h. 
   Recovered titer (Log PFU/ml) 
Time 
(Min) 
PBS 
Ethanol 
(10%) 
B-PAC 
(0.5 mg/ml) 
B-PAC 
(1 mg/ml) 
B-PAC 
(2 mg/ml) 
B-PAC 
(5 mg/ml) 
15 4.81 ± 0.05
A
 4.80 ± 0.04
A
 NP** 3.27 ± 0.08
B
 2.79 ± 0.16
C
 2.35 ±0.12
C
 
30 4.78 ± 0.03
A
 4.75 ± 0.03
A
 NP** 3.07 ± 0.24
C
 0
D
 0
D
 
60 4.83 ± 0.07
A
 4.71 ± 0.13
A
 4.28 ± 0.11
A
 2.58 ± 0.14
C
 0
D
 0
D
 
180 4.85 ± 0.12
A
 4.77 ± 0.16
A
 4.06 ± 0.18
AB
 0
D
 0
D
 0
D
 
360 4.81 ± 0.13
A
 4.61 ± 0.16
A
 4.12 ± 0.09
AB
 0
D
 0
D
 0
D
 
A, B, C
 Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
**NP= not performed 
 
Table 2.4 Reduction of Aichi Virus (AiV) by blueberry proanthocyanidins (B-PAC) at 37
o
C over 24 h. 
  Recovered titer (Log PFU/ml) 
Time 
(Hour) 
PBS
a
 
Ethanol 
(10%) 
B-PAC 
(1 mg/ml) 
B-PAC 
(2 mg/ml) 
B-PAC 
(5 mg/ml) 
0.5 4.75 ± 0.07
A
 4.57 ± 0.14
A
    4.27 ± 0.08
AB
 3.82±0.17
B
 3.36 ± 0.11
B
 
1 4.62 ± 0.04
A
 4.53 ±0.06
A
 3.12±0.10
C
 2.99±0.26
C
 2.86±0.58
C
 
3 4.53 ± 0.05
A
 4.58 ± 0.08
A
 2.69±0.29
C
 2.71±0.12
C
 0
D
 
6 4.45 ± 0.11
A
 4.59 ± 0.07
A
 3.00±0.36
C
 0
D
 0
D
 
24 4.43 ± 0.06
A
 4.52 ± 0.07
A
 2.30±0.00
C
 0
D
 0
D
 
A, B, C
 Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml 
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Table 2.5 Effect of blueberry juice (BJ) on FCV-F9 at ~ 5 log PFU/ml at 37
o
C over 6h. 
  Recovered titer (Log PFU/ml) 
Time 
(Min) 
PBS 
Malic acid 
 (pH 3.0) 
Blueberry Juice 
 (pH 2.8) 
Neutralized  
Blueberry Juice  
(pH 7.0) 
30 4.83 ± 0.05
A
 4.85 ± 0.04
A
    4.39 ± 0.08
B
 4.87 ± 0.03
A
 
60 5.17 ± 0.10
A
 4.85 ± 0.04
A
 3.58 ± 0.09
C
 4.84 ± 0.08
A
 
120 5.17 ± 0.10
A
  4.80 ± 0.03
A
 2.76 ± 0.30
D
 4.74 ± 0.02
A
 
180 4.85 ± 0.05
A
  4.39 ± 0.12
B
 0
E
 4.77 ± 0.04
AB
 
360 4.99 ± 0.07
A
 4.39 ± 0.12
B
 0
E
 4.76 ± 0.03
AB
 
A, B, C, D, E 
Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
 
     
 
Table 2.6 Effect of blueberry juice (BJ) on MNV-1 at ~ 5 log PFU/ml at 37
o
C over 6 h. 
  Recovered titer (Log PFU/ml) 
Time 
(Hour) 
PBS 
Malic acid 
 (pH 3.0) 
Blueberry Juice 
 (pH 2.8) 
Neutralized  
Blueberry Juice  
(pH 7.0) 
1 4.57 ± 0.07
A
 4.79 ± 0.04
A
 4.33 ± 0.05
A
 4.33 ± 0.05
A
 
3 4.75 ± 0.07
A
    4.78 ± 0.02
A
    4.26 ± 0.12
B
 4.26 ± 0.12
A
 
6 4.50 ± 0.07
A
 4.45 ± 0.05
A
    4.02 ± 0.13
 AB
   4.02 ± 0.13
AB
 
24 4.04 ± 0.19
 C
    4.12 ± 0.09
 AB
 0
D
 3.88 ± 0.18
C
 
A, B, C
 Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
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Table 2.7 Effect of blueberry juice (BJ) on HAV at ~ 5 log PFU/ml at 37
o
C over 24 h. 
  Recovered titer (Log PFU/ml) 
Time 
(Hour) 
PBS 
Malic acid 
 (pH 3.0) 
Blueberry Juice 
 (pH 2.8) 
Neutralized  
Blueberry Juice  
(pH 7.0) 
1 4.78 ± 0.04
A
 4.76 ± 0.05
A
 3.63 ± 0.07
A
 4.73 ± 0.05
A
 
2 4.77 ± 0.02
A
 4.77 ± 0.07
A
 3.85 ± 0.05
B
 4.72 ± 0.02
A
 
3 4.90 ± 0.05
A
 4.76 ± 0.05
A
 3.63 ± 0.32
BC
 4.79 ± 0.03
A
 
6 4.80 ± 0.05
A
 4.47 ± 0.12
A
 3.45 ± 0.05
C
 4.52 ± 0.22
A
 
24 4.63 ± 0.07
A
 4.32 ± 0.04
A
 2.77 ± 0.12
D
 4.52 ± 0.22
A
 
A, B, C, D
 Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
 
Table 2.8 Effect of blueberry juice (BJ) on Aichi virus (AiV) at ~ 5 log PFU/ml at 37
o
C over 24 h. 
   Recovered titer (Log PFU/ml) 
Time 
(Hours) 
PBS
a
 
Malic acid 
 (pH 3.0) 
Blueberry 
Juice 
 (pH 2.8) 
Blueberry 
Juice 
 (pH 7.0) 
1 4.62 ± 0.04
A
 4.54 ± 0.04
A
 4.45 ± 0.10
A
 4.55 ± 0.15
A
 
3 4.53 ± 0.05
A
 4.28 ± 0.11
A
 3.26 ± 0.04
B
 4.53 ± 0.05
A
 
6 4.45 ± 0.11
A
 3.61± 0.25
B
 2.72 ± 0.34
C
 4.39 ± 0.18
A
 
24 4.43 ± 0.06
A
 0
D
 0
D
 4.20 ± 0.17
A
 
A, B, C, D
 Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml
98 
 
Chapter 3 Blueberry proanthocyanidins against human enteric 
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Abstract 
 
Blueberry proanthocyanidins (B-PAC) are known to decrease foodborne virus titers. The 
application of B-PAC as therapeutic or preventive options against foodborne viral illness needs 
to be determined using model foods and simulated gastric conditions in vitro. The objective of 
this study was to evaluate the antiviral effect of B-PAC in model foods (apple juice; AJ and 2% 
reduced fat milk) and simulated gastrointestinal fluids against human norovirus surrogates (feline 
calicivirus; FCV-F9 and murine norovirus; MNV-1), hepatitis A virus (HAV) and Aichi virus 
(AiV) over 24 h at 37
o
C. Equal amounts of each virus (5 log PFU/ml) were individually mixed 
with either B-PAC (1, 2 and 5 mg/ml) made in AJ or 2% milk or simulated intestinal fluid 
controls or controls including phosphate buffered saline or malic acid (pH 7.2) or apple juice or 
2% milk over 24h at 37
o
C. All tested viruses were reduced to undetectable levels within 15 min 
with B-PAC (1, 2 and 5 mg/ml) in AJ (pH 3.6). B-PAC activity was reduced in milk, where 
significant reduction in titers were obtained only after 24 h. FCV-F9 was reduced by 0.4 and 
1.09 log PFU/ml with 2 and 5 mg/ml, respectively and MNV-1 titers were reduced by 0.81 log 
PFU/ml with 5 mg/ml after 24 h in milk. For HAV, reductions of 0.54 and 0.83 log PFU/ml with 
2 and 5 mg/ml, respectively after 24 h in milk were obtained. With AiV, reductions of 0.52 and 
0.84 log PFU/ml were obtained with 2 and 5 mg/ml after 24h. B-PAC at 5 mg/ml in simulated 
intestinal fluid reduced titers of all four tested viruses to undetectable levels within 30 min. 
Overall, these results show potential for B-PAC as preventive and therapeutic options for 
foodborne viral illnesses.  
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Introduction 
 
Foodborne enteric viruses are commonly associated with non-bacterial acute gastroenteritis in 
humans (1). Epidemiologically significant foodborne diseases include human noroviruses, 
hepatitis A virus, rotaviruses, Aichi virus, hepatitis E virus, adenoviruses, sapovirus, astrovirus, 
parvoviruses and other enteroviruses (2). However, some of these viruses such as human 
norovirus and Aichi virus do not have vaccines available for their control. Natural plant extracts 
have been used for their valuable medicinal properties since centuries (3). Extracts from plant 
and fruit sources are known to contain abundant secondary metabolites mainly phenolic 
compounds including but not limited to anthocyanidins, proanthocyanidins, catechins, 
epicatechin gallate and tannins (3). Plant extracts are being studied extensively as sustainable 
sources of potential therapeutic options, due to their low cost and consumer appeal (4). Among 
the array of potential health benefits, these extracts are being screened for their antiviral potential 
as well (3, 4). 
In absence of specific treatment strategies or control measures for many of these viruses, 
natural extracts provide novel alternatives to control of their spread and prevent their 
transmission. Blueberries have gained increasing popularity for consumption due to their 
associated broad spectrum of health benefits in the prevention of cardiovascular disorders and 
age-induced oxidative stress, combined with antioxidative, anti-inflammatory, anti-carcinogenic, 
neuro-protective, cardio-protective, antibacterial, and antiviral properties (5). Blueberries contain 
polyphenols including anthocyanins, flavonoids and proanthocyanidins (PAC) (6). Our lab has 
recently reported the antiviral effects of blueberry juice and blueberry juice proanthocyanidins 
(B-PAC) against human norovirus surrogates and hepatitis A virus at 37
o
C in vitro. However, for 
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B-PAC to be used as a therapeutic antiviral agent, its effectiveness in complex food matrices and 
gastrointestinal fluids that mimic digestion needs to be evaluated. It is well known that the 
effectiveness of antimicrobials decrease in the presence complex food matrices. Food 
components such as carbohydrates, lipids, proteins, salts, or other acidic or alkaline conditions 
may affect the antimicrobial properties of a given compound (7-14). Apple juice and milk have 
been used extensively as model food systems in various studies that evaluated efficiency of 
antimicrobials in food environments (7, 14, 15). With this information, the objective of this study 
was to assess the antiviral effects of B-PAC in model food systems (apple juice and 2% reduced 
fat milk) and in simulated gastrointestinal fluids against human noroviruses (using cultivable 
surrogates such as feline calicivirus (FCV-F9) and murine norovirus (MNV-1)), hepatitis A virus 
(HAV) and Aichi virus (AiV) over 24h at 37
o
C. 
 
Materials and methods 
Viruses and host cell lines 
 
Feline calicivirus (FCV-F9) and host Crandell Reese Feline Kidney (CRFK) cells were 
purchased from ATCC (Manassas, VA). Murine norovirus (MNV-1) was kindly gifted by Dr. 
Skip Virgin (Washington Univ., St. Louis, MO) and RAW 264.7 cells were obtained from the 
University of Tennessee at Knoxville. Hepatitis A virus (HAV; strain HM175) and fetal rhesus 
monkey kidney (FRhK4) cells were provided by our collaborator, Dr. Kalmia Kniel (University 
of Delaware). Aichi virus (AiV) was kindly provided by Dr. David Kingsley (USDA ARS, 
Delaware) and propagated using host Vero cells. Host cell lines were maintained using 
Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM-F12; HyClone Laboratories, Logan, 
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UT) containing 2 or 10% heat-inactivated fetal bovine serum (FBS, HyClone Laboratories) and 
1x Anti-Anti (Antibiotic-Antimycotic, Invitrogen, Grand Island, NY) at 37ºC in an atmosphere 
containing 5% CO2 as described earlier (16). 
Assessment of antiviral activity in model food systems 
Each virus was individually mixed with equal amounts of treatments that included B-PAC (2, 4 
and 10 mg/ml dissolved in either apple juice (pH 3.6) or 2% milk to obtain a final titer of ~5 log 
PFU/ml. Controls included each individual virus mixed in apple juice (AJ; pH 3.6) or 2% milk or 
malic acid (pH 3.0) to obtain a final titer of ~5 log PFU/ml. Treatments were incubated at 37ºC 
over 5, 15, 30, 60, 120, 180, 360 min or 24h and stopped/neutralized by adding to cell-culture 
media containing 10% heat-inactivated fetal bovine serum (FBS), followed by serial dilutions in 
cell-culture media containing 2% FBS. The infectivity of the viruses was evaluated using 
standard plaque assays as described before (17). Each experiment was replicated thrice and 
assayed in duplicate. 
Antiviral activity under simulated gastrointestinal conditions 
Equal amounts of viruses at (~6 log PFU/ml) were mixed in a ratio of 1:10 of with phosphate 
buffered saline (PBS; 7.2 as control) or malic acid control (pH 1.5) or simulated intestinal fluid 
(SIF; pH 7.5, obtained from Fisher Scientific, USA, Waltham, MA, USA), simulated gastric 
fluid (SGF; pH 1.5, obtained from Fisher Scientific, USA, Waltham, MA, USA), or B-PAC (5 
mg/ml) made in SIF or SGF and incubated at 37ºC for 1, 3, 6 and 24 h. Sodium carbonate 
(Na2CO3; 200mM) was used to neutralize the reaction mixture as described earlier and followed 
by serial dilution in cell-culture media containing 2% FBS (18). Virus infectivity was evaluated 
using standard plaque assays that were carried out in duplicates and replicated thrice. 
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Statistical analysis 
Data obtained from the three replications for each individual virus were statistically analysed 
using ANOVA with SAS software (version 9.3, SAS Institute, Cary, NC, USA) and Tukey’s test 
using a completely randomized design model as described in previous studies to determine 
statistically significant differences between the viral titers recovered from treatments and 
controls. 
Results 
Antiviral activity in model food systems 
Antiviral activity of B-PAC was shown to be the highest when prepared in apple juice (pH 3.6). 
FCV-F9 titers were reduced to undetectable levels (< 2 log PFU/ml; limit of detection of the 
assay) within 15 min at 37
o
C with 1, 2 and 5 mg/ml of B-PAC (Table 1a). However, the antiviral 
activity was impeded to a large extent when B-PAC was made in 2% reduced fat milk. Titer 
reductions of 0.40±0.03 and 1.12±0.01
 
log PFU/ml were obtained after 24h with 1, 2 and 5mg/ml 
respectively. After 6h of treatment, reductions of 0.33±0.05, 0.44±0.16 log PFU/ml were 
obtained with 2 and 5mg/ml respectively (Table 3.1). The milk control caused a reduction of 
0.96±0.23 log PFU/ml after 24 h (Table 3.2).  
MNV-1 showed a similar trend, where reduction to undetectable levels was obtained 
when B-PAC was prepared in AJ with all three concentrations (1, 2 and 5 mg/ml) within 15 min 
(Table 3.3). However, when treated with B-PAC in 2% milk, minor reductions of 0.18±0.01 and 
0.05±0.02, PFU/ml were obtained after 6h with 2 and 5 mg/ml, respectively and 0.81±0.18 log 
PFU/ml after 24h with 5 mg/ml (Table 3.4). 
B-PAC prepared in AJ caused HAV titers to reduce to undetectable levels within 15 min with 1, 
2 and 5 mg/ml (Table 3.5). When B-PAC was prepared in 2% milk, reductions of 0.54±0.15 and 
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0.83±0.04 log PFU/ml were obtained after 24h treatment with 2 and 5 mg/ml concentration of B-
PAC. After 6h of treatment, reductions of 0.15±0.01 and 0.13±0.02 log PFU/ml were obtained 
for 2 and 5 mg/ml B-PAC (Table 3.6).  
B-PAC made in AJ had increased antiviral activity where reduction to undetectable levels 
(< 2 log PFU/ml) was obtained after treatment with 2 and 5 mg/ml B-PAC in AJ after 30 min at 
37
o
C. However, the AJ control by itself did not cause any significant change in titers after 3 h of 
treatment (Table 3.7). Reduced antiviral activity of B-PAC was seen when prepared in 2% 
reduced fat milk, where titer reductions of 0.14±0.01, 1.4±0.14, 0.84±0.03 log PFU/ml were 
obtained with 5 mg/ml B-PAC in milk after 3, 6 and 24 h. Reductions of 0.29±0.01, 0.39±0.19 
and 0.52±0.17 were obtained with 2 mg/ml B-PAC in milk after 3, 6 and 24 h. The milk control 
caused a reduction of 0.48±0.19 log PFU/ml after 24 h (Table 3.8). No significant reduction with 
B-PAC in milk at any concentration was obtained with 1 or 3h treatment for FCV-F9, MNV-1, 
HAV or AiV. Moreover the AJ control did not change titers of the four tested viruses over 3h.  
Antiviral activity under simulated gastrointestinal conditions 
Simulated gastric fluid (SGF; pH 1.5) experiments were not conducted with FCV-F9 given its 
sensitivity to low pH (19). MNV-1, HAV and AiV did not survive in the SGF control; hence the 
treatments with B-PAC under gastric conditions were inconclusive. With SIF (pH 7.5), B-PAC at 
5 mg/ml reduced titers of all four tested viruses within 30 min (Table 3.9). 
Discussion 
 
B-PAC and BJ have been shown to be highly effective in reducing the titers of all the four tested 
viruses when made in 10% ethanol where the antiviral activity was found to be both time and 
concentration dependent. However, for potential application of B-PAC as an antiviral 
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therapeutic, evaluating its activity in model food systems and gastrointestinal conditions is 
necessary. Amid the two food systems, the effectiveness of treatments was seen to be higher in 
AJ compared to the effects of B-PAC in 10% ethanol, where higher titer reductions in lesser time 
were obtained. For instance, MNV-1 titers were reduced to undetectable levels after 3h with 5 
mg/ml B-PAC, however when 5 mg/ml B-PAC was made in AJ, similar reduction was obtained 
within 15 min. When tested as a control, AJ at pH 3.6 alone did not cause any significant 
reduction in titers over 3h for all four viruses. These observations suggest that the enhanced 
antiviral activity of B-PAC in AJ could be a synergistic effect of PAC together with the low pH 
of AJ as well as the presence of polyphenols like hydroxycinnamic acid and chlorogenic acid in 
AJ (20).  
Previous research carried out to test effectiveness of antimicrobials in food systems points to 
similar observations. A study examined the antimicrobial effect of seaweed Himanthalia 
elongata in carbohydrate (glucose) and protein (bovine serum albumin) model food systems 
against Salmonella abony and Listeria monocytogenes (21). The extract at concentration of 8 
mg/ml was shown to cause 100% inhibition of both Salmonella abony and L. monocytogenes 
after 24h at 37
o
C. The efficacy was reported to be dose dependent with lower concentration of 2 
mg/ml causing only 48.4% inhibition and no inhibition at 1 mg/ml. In protein system, 100% 
inhibition for both organisms was reported at 8 mg/ml extract and lower inhibition with lower 
concentrations. An interesting observation reported by the study was that the antimicrobial 
efficacy of the extract increased with increasing concentration of glucose, which was attributed 
to a possible synergistic effect where glucose can lower water activity restricting microbial 
growth.  
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When B-PAC was prepared in 2% milk, a sharp decline in effectiveness was seen where 
significant titer reductions were obtained only after 24h of treatment for all tested viruses. 
Similar results were demonstrated in a previous study where grape seed extract in the presence of 
bovine serum albumin (0.3 g/liter) was reported to have reduced antiviral activity against MNV-
1, implying that organic load such as protein interferes with the effectiveness of treatments (22). 
In this study too, reduced activity with increasing organic load was observed in model food 
systems. This could possibly be due to the inhibition from the carbohydrates, lipids and proteins 
present in the milk matrix. Peppermint oil and eugenol were tested in a study for their 
antimicrobial activity against Bacillus cereus, Staphylococcus aureus, and Escherichia coli in 
model food systems. In cabbage and barley model systems, significant reduction was reported 
for all four organisms with 0.4 % and 0.4% concentration after 28 days of storage at 37
o
C (23). 
In another study, cinnamon bark essential oil at 1,000 was shown cause a 1 log CFU/ml 
reduction of L. monocytogenes in whole milk as compared to 3 log CFU/ml reduction in 
skimmed milk indicating that higher fat content can hamper the antimicrobial effect (14). In the 
present study, 2% milk control was seen to cause a reduction of 0.96 and 0.46 log PFU/ml in 
FCV-F9 and AiV titers after 24 h. Previous studies have shown that milk components like 
lactoferrin can inhibit adsorption of hepatitis C virus (HCV) to host cells by binding to the 
envelope proteins E1 and E2 (24, 25). Similarly, lactoferrin was reported to inhibit adsorption of 
rotavirus to its host cells by binding to the virus particle (26). Lactoferrin was also reported to 
inhibit entry of poliovirus into host cells by blocking of receptors (27). However, lactoferrin 
might lose some of its activity after pasteurization. Thus if B-PAC is prepared in a food matrix 
that has inherent antiviral activity, synergistic effects can be further exploited to make it a better 
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antiviral alternative. B-PAC can be encapsulated or nano-emulsions can be developed using 
conjugates such as sodium caesinate for better dispersion and solubility. In a study, sodium 
caesinate encapsulated thymol was shown to have better dispersion properties and significantly 
higher antimicrobial activity against L. monocytogenes in milk as compared to the free thymol 
(28). The conjugate was shown to be stable at neutral pH, however at pH of 4.6, soybean 
polysaccharide was used for preventing aggregation. Similar approach could be used to develop 
B-PAC as an antiviral therapeutic thus helping it retain its antiviral activity even in presence of 
food matrices. 
To be able to exploit antiviral properties of B-PAC, it is particularly important to study its 
effect under conditions that it will possibly encounter during consumption. Furthermore, it is also 
important that the antiviral effects of the said therapeutic be maintained in the low pH and 
conditions of the gastrointestinal tract. Both SGF and SIF were chosen to study effect of 
treatment under different pH conditions (pH of SIF is 1.5 and pH of SGF is 7.5) and gut enzymes 
like pepsin and pancreatin, as they would be subject in vivo. However, the tested viruses did not 
survive in the simulated gastric fluid (pH 1.5). This could possibly be due to the fact that MNV-1 
as a human norovirus surrogate was used and it could not mimic the survival of human norovirus 
at such low pH. The same could be true with HAV, since the strain HM175 used in the study is a 
lab-adapted strain that did not respond to the low pH in a manner similar to the wild type strain.  
Another possible reason for their survival in vivo could also be due to their binding to mucus or 
protection from food during the stomach transit, so they are protected from the enzymatic 
environment. Antimicrobial activity of T. camphoratus crude methanolic and water extract 
(minimum inhibitory concentration of 2 mg/ml) at 37
o
C after 24h was reduced after exposure to 
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simulated gastric fluid (29). The study suggested that exposure to gastric fluid caused chemical 
alteration or degradation of the active compounds leading to decreased antimicrobial activity. In 
this study, since the viruses did not survive in the gastric fluid, it was difficult to conclude the 
fate of B-PAC upon exposure to gastric environment.  
 This study will help provide a better understanding on the effective optimum 
concentration levels and time required to inactivate the target viruses for use as antiviral therapy. 
The reported results might be able to provide useful data for designing where time-release or 
dosage for these antiviral compounds. Additionally, animal feeding studies with blueberries and 
B-PAC using pre- and post-challenge should be carried out to determine antiviral effects. In 
addition, “omics” approaches (metagenomic analysis and next generation sequencing) can be 
used to determine changes in the gut microbiota that could enhance growth of beneficial 
microflora to prevent gastrointestinal disease. However, before any recommendations for 
consumption as therapeutic options can be suggested or health claims made, clinical trials and 
regulatory approvals will be needed and hence in vitro data must be interpreted with caution as 
indicated in earlier reports (30). 
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Appendix C 
Table 3.1 Effect of blueberry proanthocyanidins (B-PAC) in apple juice (AJ) on FCV-F9 titers over 3h at 37
0
C 
  
Time 
(min) 
Recovered titer (Log PFU/ml) 
PBS
a
 
(pH 7.2) 
AJ 
(pH 3.6) 
B-PAC in 
AJ 
(1 mg/ml) 
B-PAC in 
AJ 
(2 mg/ml) 
B-PAC in 
AJ 
(5 mg/ml) 
15 4.79 ± 0.14
 A
 4.70 ± 0.10
 A
 0
 *B
 0
 *B
 0
 *B
 
30 4.83 ± 0.05
A
 4.88 ± 0.05
 A
 0
 *B
 0
 *B
 0
 *B
 
60 5.03 ± 0.06
A
 4.86 ± 0.06
 A
 0
 *B
 0
 *B
 0
 *B
 
 
a -  phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences 
between treatments (P < 0.05).  
 
Table 3.2 Effect of blueberry proanthocyanidins (B-PAC) in 2% milk on FCV-F9 titers over 24h at 37
0
C 
  
Time 
(Hours) 
Recovered titer (Log PFU/ml) 
PBS
a
 
 
2% Milk 
B-PAC in 2% 
Milk 
(2 mg/ml) 
B-PAC in 2%  
Milk 
(5 mg/ml) 
3 4.85 ± 0.05
A
 4.10 ± 0.02
 AB
 4.76 ±0.02
 A
 4.67 ±0.11
 A
 
6 4.99 ± 0.07
A
 4.10 ± 0.05
 AB
 4.66 ±0.12
 A
            4.55 ±0.23
 A
 
24 4.75 ± 0.07
 A
 3.79 ± 0.30
 B
 4.35 ±0.10
 A
            3.66 ± 0.06
 B
 
 
a -  phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences 
between treatments (P < 0.05).  
 
 
 
114 
 
Table 3.3 Effect of blueberry proanthocyanidins (B-PAC) in apple juice (AJ) on MNV-1 titers over 3h at 37
0
C 
  Recovered titer (Log PFU/ml) 
Time 
(min) 
PBS
a
 
 (pH 7.2) 
AJ  
(pH 3.6) 
B-PAC in 
AJ 
(1 mg/ml) 
B-PAC in 
AJ 
(2 mg/ml) 
B-PAC in 
AJ 
(5 mg/ml) 
15 4.74 ± 0.24
 A
 4.76 ± 0.19
 A
 0
 *B
 0
 *B
 0
 *B
 
30 4.89 ± 0.08
A
 4.76 ± 0.19
 A
 0
 *B
 0
 *B
 0
 *B
 
60 4.84 ± 0.10
A
 4.76 ± 0.19
 A
 0
 *B
 0
 *B
 0
 *B
 
a -  phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences 
between treatments (P < 0.05).  
 
 
 
Table 3.4 Effect blueberry proanthocyanidins (B-PAC) in 2% milk on MNV-1 titers over 24h at 37
0
C 
  Recovered titer (Log PFU/ml) 
Time 
PBS
a
 
 
2% Milk 
B-PAC in 2% 
milk 
(2 mg/ml) 
B-PAC in 2%  
milk 
(5 mg/ml) (Hours) 
3 4.90 ± 0.10
 A
 4.92 ± 0.02
 A
 4.51 ± 0.07
 A
 4.53 ± 0.09
 A
 
6 4.75 ± 0.07
A
 4.94 ± 0.02
 A
 4.57 ± 0.06
 A
 4.80 ± 0.05
 A
 
24 4.50 ± 0.07
A
 4.91 ± 0.01
 A
 4.66 ± 0.04
 A
 3.69 ± 0.25
 B
 
a -  phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences 
between treatments (P < 0.05).  
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Table 3.5 Effect of blueberry proanthocyanidins (B-PAC) made in apple juice (AJ) on HAV titers over 3h at 37
0
C 
  Recovered titer (Log PFU/ml) 
Time 
(min) 
PBS 
(pH 7.2) 
AJ 
(pH 3.6) 
B-PAC in 
AJ 
(1 mg/ml) 
B-PAC in 
AJ 
(2 mg/ml) 
B-PAC in 
AJ 
(5 mg/ml) 
15 5.09 ± 0.04
 A
 4.87 ± 0.05
 A
 0
 *B
 0
 *B
 0
 *B
 
30 4.81 ± 0.05
A
 4.86 ± 0.06
 A
 0
 *B
 0
 *B
 0
 *B
 
60 4.78 ± 0.03
A
 4.70 ± 0.05
 A
 0
 *B
 0
 *B
 0
 *B
 
a -  phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences 
between treatments (P < 0.05).  
 
 
 
Table 3.6 Effect of blueberry proanthocyanidins (B-PAC) made in 2% milk on HAV titers over 24h at 37
0
C 
Time 
(hours) 
Recovered titer (Log PFU/ml)  
PBS
a
 
 
2% Milk 
B-PAC in 2% 
milk 
(2mg/ml) 
B-PAC in 2%  
milk 
(5mg/ml) 
3 5.09 ± 0.04
 A
 4.87 ± 0.05
 A
 4.87 ± 0.03
 A
 4.80 ± 0.08
 A
 
6 4.90 ± 0.05
A
 4.76 ±0.07
 A
 4.75 ± 0.04
 A
 4.77 ± 0.07
 A
 
24 4.98 ± 0.08
 A
  4.67 ± 0.14
 A
 4.44 ± 0.23
 A
 4.15 ± 0.12
 B
 
 
a -  phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences 
between treatments (P < 0.05).  
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Table 3.7 Effect of blueberry proanthocyanidins (B-PAC) prepared in apple juice (AJ) on Aichi virus (AiV) at ~ 5 log PFU/ml 
over 24h at 37
o
C 
  
 
Recovered titer (Log PFU/ml) 
Time 
PBS
a
  
(pH 7.2) 
AJ 
(pH 3.6) 
NAJ 
(pH 7.0) 
Blueberry 
PAC in AJ 
(1 mg/ml) 
Blueberry 
PAC in AJ 
(2 mg/ml) 
(Hours) 
0.5 4.79 ± 0.14A 4.70 ± 0.10 A 4.49 ± 0.09 A 0
*B
 0
*B
 
1 4.75 ± 0.07 A 4.80 ± 0.10 A 4.42 ± 0.04 A 0
*B
 0
*B
 
3 4.53 ± 0.05 A 4.56 ± 0.22 A 4.42 ± 0.15 A 0
*B
 0
*B
 
 
Table 3.8 Effect of blueberry proanthocyanidins (B-PAC) prepared in 2% milk on Aichi virus (AiV) over 24h at 37
o
C 
  Recovered titer (Log PFU/ml) 
Time 
PBS
a
 2% Milk 
Blueberry 
PAC in 2% 
Milk 
(2 mg/ml) 
Blueberry 
PAC in 2% 
Milk 
(5 mg/ml) 
(Hours) 
3 4.60 ± 0.13A 4.35 ± 0.05A 4.31 ± 0.12A 4.46 ± 0.11A 
6 4.58 ± 0.30A 4.13 ± 0.02A 4.19 ± 0.11A 3.18 ± 0.16C 
24 4.43 ± 0.05A 3.95 ± 0.24B 3.91 ± 0.22B 3.59 ± 0.08B 
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Table 3.9 Effect of B-PAC (5 mg/ml) prepared in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) against 
FCV-F9, MNV-1, HAV and AiV (~ 5 log PFU/ml) over 1 h at 37ºC 
Virus Treatment 
Time in hours 
0.5 1 
Recovered titer (Log PFU/ml) 
FCV-F9  
PBS
a
 (pH 7.2) 4.76 ± 0.06
 A
 4.80 ± 0.03
 A
 
SIF (pH 7.5) 4.79 ± 0.25
 A
 4.79 ± 0.25
 A
 
B-PAC in SIF 0
 *B
 0
 *B
 
MNV-1 
PBS
a
 (pH 7.2) 4.95 ± 0.07
 A
 4.95 ± 0.07
 A
 
SIF (pH 7.5) 4.84 ± 0.09
 A
 4.77 ± 0.09
 A
 
SGF (pH 1.5) 0
 *B
 0
 *B
 
B-PAC in SIF 0
 *B
 0
 *B
 
HAV 
PBS
a
 (pH 7.2) 4.77 ± 0.01
 A
 4.78 ± 0.04
7A
 
SIF  (pH 7.5) 4.61 ± 0.01
 A
 4.50 ± 0.03
 A
 
SGF (pH 1.5) 0
 *B
 0
 *B
 
B-PAC in SIF 0
 *B
 0
 *B
 
AiV 
PBS
a
 (pH 7.2) 4.79 ± 0.14
A
 4.75 ± 0.07
A
 
SIF  (pH 7.5) 4.41 ± 0.05
A
 4.44 ± 0.21
A
 
SGF (pH 1.5) 0
 *B
 0
 *B
 
B-PAC in SIF 0
 *B
 0
 *B
 
a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences 
between treatments (P < 0.05).  
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Chapter 4 Understanding the mechanism of antiviral activity of 
blueberry juice and blueberry proanthocyanidins 
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Abstract 
 
Blueberry polyphenols have demonstrated effective antiviral properties against cultivable human 
norovirus surrogates, Aichi virus, and hepatitis A virus. The objectives of this study were to (a) 
compare the antiviral activity of the monomeric catechin monohydrate, procyanidin B2, B-type 
PAC from blueberries (B-PAC) and A-type PAC from cranberries (C-PAC) against hepatitis A 
virus (HAV), Aichi virus (AiV) and the cultivable human norovirus surrogates, feline calicivirus 
(FCV-F9) and murine norovirus (MNV-1) at 37ºC by plaque assays; (b) determine the effect of 
blueberry proanthocyanidins (B-PAC) on viral adsorption and viral replication of HAV, AiV, 
FCV-F9 and MNV-1 at 37ºC using plaque assays; (c) determine effects of B-PAC on virus 
structure using Transmission Electron Microscopy (TEM) and enzyme linked immunosorbent 
assays (ELISA). Experiments were carried out in duplicate, replicated thrice, and data were 
analyzed statistically analyzed. Monomeric catechins at 1 mg/ml reduced FCV-F9 titers to 
undetectable levels within 1 h and MNV-1 after 24h, AiV by 0.66 log PFU/ml after 24h, without 
any significant effect on HAV. Procyanidin B2 at 1 mg/ml reduced FCV-F9 to undetectable 
levels after 3h, with 1.23, 0.04 and 0.67 log PFU/ml reduction for MNV-1, HAV and AiV after 
24h. Pre-treatment of host cells with 0.5 mg/ml B-PAC showed that FCV-F9, MNV-1, HAV and 
AiV titers were reduced by 0.63, 0.53, 0.34 and 0.62 log PFU/ml indicating that B-PAC had 
modest effects on preventing viral adsorption. However, lower reduction after post-infection 
treatment was obtained. TEM observations revealed moderate effect on the structure of the viral 
particles with either damaged viral capsid or binding by PAC, possibly preventing their 
attachment to host cells. These results provide insights for use of blueberry polyphenols in 
developing preventive antiviral therapies. 
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Introduction 
 
With the rise in number of foodborne diseases caused by enteric viruses, there is a need to 
develop effective mitigation strategies for their control. In the current absence of vaccination or 
effective treatment options for human norovirus infections, natural alternatives are being 
evaluated (1). Plant derived polyphenols and their associated health benefits as antimicrobials 
against bacteria are well established (2-5). Likewise, blueberries are known to have a broad 
spectrum of health benefits such as prevention of cardiovascular disorders, age-induced oxidative 
stress, inflammatory responses, and diverse degenerative diseases along with anti-carcinogenic, 
neuro-protective, cardio-protective, antibacterial, and antiviral properties (6). Blueberries contain 
polyphenols including anthocyanins, flavonoids and proanthocyanidins (PAC), also referred to as 
condensed tannins (7). Tannins (condensed and hydrolysable) differ from other phenolic 
compounds for they are able to precipitate proteins, known as astringency (8). PAC’s are dimers, 
oligomers, and polymers of catechins bound together by linkages between C4 and C8 (or C6) 
where the monomeric flavanols differ in the stereochemistry of C-3 and their hydroxylation 
pattern in ring A and B (9). Many plant foods, including blueberries, apples and grapes contain 
high amounts of PACs, but only a few contain A-type PACs (10). The polymerized PACs in 
blueberries contain A-type linkages, with different profiles and amounts as compared to 
cranberries (11). Cranberries contain PAC’s with A-type linkage accounting for 51– 91% of total 
PACs (10). B-type proanthocyanidins can be converted to A-type proanthocyanidins by radical 
oxidation (12) Distinction between A- and B-type PAC structures is of importance because the 
difference can influence their biological properties. The A-type PACs exhibit significantly 
greater inhibition of adhesion of P-fimbriated Escherichia coli to uroepithelial cells in vitro than 
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the B-type PACs, which is the initial step in the development of urinary tract infection (UTI) 
(13). Blueberries have been known to contain around 88-261 mg of proanthocyanidin/100 gram 
of edible portion as per the USDA database for flavonoid content (USDA Database for the 
proanthocyanidin Content of Selected Foods, August 2004). The recommended dose for 
blueberries in daily diet can be 1 to 2 cup serving of fresh or frozen blueberries per day, and 
consumption of more than 100 gram fruit per day may be required for health benefits. The 
blueberry PAC concentration range used in our study is from 1 to 5 mg/ml that compares to 
eating about ¼ of the daily serving size.  
Several attempts have been made at understanding the mode of antiviral action of natural 
plant polyphenols against human noroviral (HNoV) surrogates, feline calicivirus (FCV-F9), 
murine norovirus (MNV-1) using various techniques such as electron microscopy studies, 
binding studies, molecular assays and in vitro cell culture assays (4, 14, 15). Viruses are known 
to cross the host epithelial barrier through attachment to carbohydrate moieties of host cell 
glycoproteins, glycolipids such as sialic acid, and proteoglycans (16). Human noroviruses in 
addition to binding to histo-blood group antigens are also known to bind to porcine gastric mucin 
(PGM) (17). PGM has been used widely in studies to discriminate between infectious and non-
infectious norovirus particles (18). ELISA (enzyme-linked immune sorbent assay) involving 
differential binding of viral particles with intact and non-intact capsid to PGM has been used to 
determine viral infectivity (Hirneisen and Kniel, 2012). Briefly, only those viruses that have an 
intact capsid after inactivation treatments will bind to the PGM in the assay. The study assessed 
attachment of MNV-1 after heat, high-pressure, ozone and UV inactivation treatments, and 
found that only heat treatments at 80 and 100
o
C for 5 min caused a significant change in the 
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binding ability whereas other treatment did not have a significant effect on the capsid (19). 
Saliva-binding ELISA showed that grape seed extract (GSE) treatments of 0.2 and 2 mg/ml at 
37°C for 1 h caused a significant difference in the binding ability of HNoV’s, indicating that loss 
of infectivity caused by GSE treatments was due to capsid damage and thus loss in binding 
ability (4). Similar approaches could be used for determining the mechanism of action of 
blueberry juice (BJ) and B-PAC on foodborne viruses. Such assays would be useful in 
understanding the effect of treatments on capsid integrity/structure and thereby their decrease 
binding abilities. Correlation between binding studies, infectious plaque assays and TEM 
analysis could help elucidate the exact mechanism of action of these polyphenols against these 
viruses.  
The objectives of this study were to (a) compare the antiviral activity of the monomeric 
unit (Catechins) and dimeric procyanidin B2 (B- type PAC present in blueberries) to PAC in 
blueberries (B-PAC, previously published data) on infectivity of hepatitis A virus (HAV), Aichi 
virus (AiV) and human norovirus surrogates, FCV-F9 and MNV-1 at 37ºC; (b) determine the 
effect of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) on viral adsorption and 
viral replication of HAV, AiV, FCV-F9 and MNV-1 at 37ºC and (c)  determine effects of B-PAC 
on virus structure using Transmission Electron Microscopy and ELISA.  
 
Materials and Methods 
Viruses and cell lines  
Feline calicivirus (FCV-F9) and host Crandell Reese Feline Kidney (CRFK) cells were 
purchased from ATCC (Manassas, VA). Murine norovirus (MNV-1) was kindly gifted by Dr. 
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Skip Virgin (Washington Univ., St. Louis, MO) and RAW 264.7 cells were obtained from the 
University of Tennessee at Knoxville. Hepatitis A virus (HAV; strain HM175) and fetal rhesus 
monkey kidney (FRhK4) cells were provided by our collaborator, Dr. Kalmia Kniel (University 
of Delaware). All three host cell lines were maintained using Dulbecco’s Modified Eagle’s 
Medium/Ham’s F-12 (DMEM-F12; HyClone Laboratories, Logan, UT) containing 10% heat-
inactivated fetal bovine serum (FBS, HyClone Laboratories) and 1x Anti-Anti (Antibiotic-
Antimycotic, Invitrogen, Grand Island, NY) at 37ºC in an atmosphere containing 5% CO2. Aichi 
virus (AiV) was kindly provided by Dr. David Kingsley (USDA ARS, Delaware).  Host Vero 
cells were maintained in Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM-F12; 
HyClone Laboratories, Logan, UT) with 2% FBS heat-inactivated fetal bovine serum (FBS, 
HyClone Laboratories) and 1x Anti-Anti (Antibiotic-Antimycotic, Invitrogen, Grand Island, NY) 
at 37ºC in an atmosphere containing 5% CO2 as described earlier (20).  
Comparison of antiviral activity of components and types of PAC’s 
Antiviral activity of catechin hydrate (Sigma Aldrich) and procyanidin B2 (Sigma Aldrich) 
against the four viruses; FCV-F9, MNV-1, HAV and AiV was compared to the antiviral activity 
of PAC’s isolated from blueberries (B-type PAC; kindly provided as a gift by Dr. Amy Howell, 
Rutgers University) and cranberries (A-type PAC; previously published data;(21)). Equal 
amounts of each virus at 5 log PFU/ml were mixed with equal amounts of catechin hydrate (10 
or 2 mg/ml), procyanidin B2 (1 or 0.5 mg/ml), or B-PAC (all three were in powder form and 
were dissolved in 10% ethanol) and treated for 3, 6 and 24 h at 37
o
C. Reactions were stopped in 
DMEM containing 10% FBS and serially diluted in DMEM with 2% FBS. Viral infectivity was 
evaluated using standardized plaque assays (20, 21). 
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Effect of B-PAC and BJ on host cells lines 
Cytopathic effects of B-PAC, BJ (pH 2.8) and NBJ (neutralized blueberry juice; pH 7.0) 
treatments on the host cell lines were also determined. The maximum concentration of B-PAC 
used in the viral treatment and assays was 5 mg/ml, however, the host cell lines were only 
exposed to a maximum 20-fold dilution of the treatment after neutralization/stopping of 
treatment. Thus, each individual cell lines were exposed to B-PAC at 0.5 mg/ml and BJ and NBJ 
for 2h at 37
o
C and observed under optical microscope to determine visible changes. 
Effect of B-PAC and BJ on adsorption and replication 
To determine the effect of B-PAC and NBJ on viral replication, host CRFK, RAW 264.7, 
FRhK4, and Vero cells in 6-well plates were first infected with FCV-F9, MNV-1, HAV, and 
AiV respectively for 2 h, followed by treatment with B-PAC (0.5mg/ml) or NBJ for 20 min at 
37°C. To determine effects on viral adsorption/binding, the host cells were pretreated with B-
PAC (0.5 mg/ml) or NBJ for 20 min, followed by viral infection for 2 h at 37°C. Cells were then 
overlaid with complete DMEM containing 0.75% or 1% agarose. After incubation for 2 to 8 days 
at 37°C under 5% CO2, a second overlay containing neutral red was added followed by 
incubation to allow the visualization of plaques and plaques were counted and recorded as plaque 
forming units (PFU/ml) (21).  
Transmission electron microscopy (TEM) analysis 
FCV-F9, MNV-1, HAV or AiV at ~6.5 log PFU/ml were mixed with equal volumes of B-PAC (2 
mg/ml), BJ, or sterile distilled water (control) and the individual viruses were incubated at 37
o
C 
for 15 min, 1 h, 30 min and 1 h respectively (based on reduction of viral titers obtained with 
treatments). Fresh glow discharged, formvar and carbon coated copper grids were coated with 
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10-l of the viral samples, stained with uranyl acetate for 1 min and allowed to dry. The samples 
were then observed under a Hitachi H800 at 75KeV (courtesy of Dr. Dunlap at the UT-Knoxville 
Advanced Microscopy and Imaging Center).  
 
ELISA PGM binding assay  
The protocol for PGM binding ELISA was adapted from (19). ELISA plates pre-coated with 
poly-D-lysine (ThermoFisher Scientific) were coated with 100 μl of porcine gastric mucin 
(Sigma) at 10 μm/mL in Tris Buffered Saline (TBS; pH 7.6) and were incubated for 24h at 4oC. 
Plates were washed with deionized double distilled (dDI) water thrice to remove unbound 
material. Following this, the plates were blocked with Animal-Free Blocking Buffer (Vector 
Labs, Burlingame, CA) for 2 h at room temperature. The wells were washed twice with dDI 
water to remove excess blocking buffer. MNV-1 samples (treatment or control) diluted in TBS 
(upto 5 serial dilutions) were added to the wells and were allowed to incubate at 37
o
C for 1 h. 
Wells were washed thrice with dDI water followed by addition of 1:1000 dilution of monoclonal 
anti-MNV IgA (gifted by Dr. Christiane Wobus, University of Michigan) diluted in TBS and 
allowed to incubate at 37
o
C for 1 h. Unbound anti-MNV IgA was removed by washing the wells 
with TBS with 0.05% Tween- 20 (TTBS). Horseradish peroxidase (HRP)-conjugated goat anti-
mouse secondary IgA (diluted 1:5000 in TTBS) (KPL) was used for detection of bound primary 
antibody followed by incubated at 37
o
C for 1 h. Unbound secondary antibody was removed by 
washing thrice with TTBS followed by addition of 80 μL of 3,3’, 5, 5’ tetramethylbenzidine 
(TMB) liquid substrate (Thermo Fisher) and incubation at room temperature for 10 min. The 
reaction was stopped by the addition of 2M H2SO4 and absorbance was read at 450 nm. 
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Statistical analysis 
Statistical analysis was carried out using ANOVA with SAS software (version 9.3, SAS Institute, 
Cary, NC, USA) and Tukey’s test on a completely randomized design with data obtained from 
the three replications for each individual virus as described in previous studies (14, 22).  
Results 
Comparison of antiviral activity of monomeric and polymeric PAC’s 
Polymeric B-PAC at 1 mg/ml was shown to reduce FCV-F9, MNV-1 and HAV titers to 
undetectable levels within 3 h of treatment, while longer incubation time of 6h was needed to 
reduce AiV titers to undetectable levels at 37
o
C. Monomeric catechins at 1 and 5 mg/ml reduced 
FCV-F9 to undetectable levels after 6 and 3h, respectively. B-type PAC, procyanidin B2 at both 
0.5 and 1 mg/ml reduced FCV-F9 to undetectable levels after 3h (Table 4.1). MNV-1, the 
sturdier of the surrogates showed lower reduction with both monomeric catechin and procyanidin 
B2. Reductions of 0.42±0.02 and 1.76±0.13 log PFU/ml were obtained for MNV-1 with 1 and 5 
mg/ml monomeric catechin after 3h. MNV-1 titers reduced to undetectable levels after 6h with 5 
mg/ml monomeric catechin and after 24h with 1 mg/ml monomeric catechin. No significant 
reduction in MNV-1 titers was obtained with procyanidin B2, except with a reduction of 
1.23±0.11 log PFU/ml after 24h with 1 mg/ml (Table 4.2). Similarly for HAV, no significant 
reductions were obtained either with monomeric catechin or procyanidin B2 even after 24h 
(Table 4.3). AiV titer reductions of 0.36±0.20, 0.88±0.0 and 0.95±0.04 log PFU/ml were 
obtained with monomeric catechin at 5 mg/ml after 3, 6 and 24h, respectively. Monomeric 
catechin at 1mg/ml reductions of 0.77±0.02, 0.82±0.01 and 0.66±0.19 log PFU/ml after 3, 6 and 
24h respectively were obtained. Procyanidin B2 at 1 mg/ml had minimal effect on AiV titers, 
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with reductions of 0.41±0.21, 0.49±0.13 and 0.67±0.19 log PFU/ml and 0.23±0.04, 0.12±0.03 
log PFU/ml with 5 mg/ml after 3, 6 and 24h respectively were obtained (Table 4.4). 
Effect of B-PAC and BJ on host cells lines 
B-PAC at a concentration of 0.5 mg/ml was not found to be cytotoxic to the four tested host cell 
lines. Undiluted BJ when added directly to the host cells had some minor effects after 2h. 
However, neutralized BJ (NBJ) did not show any morphological visual changes in the four host 
cells and was used further in the time of addition experiments. In the experiment involving 
treatment of viruses with B-PAC, the cells are exposed to a maximum of 20-fold diluted B-PAC 
and hence the host cells do not show cytopathic/cytotoxic effects.  
Effect of B-PAC and BJ on viral adsorption and viral replication 
Treatment of host cells with 0.5 mg/ml B-PAC before viral infection reduced the titers of FCV-
F9, MNV-1, HAV and AiV by 0.63±0.01, 0.53±0.03, 0.34±0.07 and 0.62±0.34 log PFU/ml, 
respectively (Table 4.5). When the cells were treated with 0.5 mg/ml B-PAC post viral infection, 
reductions in viral titers of 0.37±0.01, 0.23±0.06, 0.03±0.01 and 0.30±0.07 log PFU/ml were 
obtained for FCV-F9, MNV-1, HAV and AiV respectively (Table 4.6). These results suggest that 
B-PAC at 0.5 mg/ml plays a modest effect in the prevention of virus attachment to the host and 
adsorption with a lesser effect on inhibiting replication. NBJ did not have any significant effect 
on viral adsorption or viral replication of all the four tested viruses. 
Transmission electron microscopy studies using B-PAC 
TEM studies were carried out with B-PAC (0.5 mg/ml) to elucidate the mechanism of action of 
B-PAC on the virus structure. B-PAC was shown to encapsulate FCV-F9 viral particles while 
some treated viruses also had structural damage with capsid disruption by TEM as shown (Fig 4 
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– 1a and b). Similar results were observed with MNV-1 where the particles were coated or 
adhered with the treatment material (Fig 4 – 2a and b), and similarly treated HAV samples 
appeared to be coated/encapsulated by B-PAC compared to the water control (Fig 4- 3a and b). 
However, TEM observations for AiV did not show any significant change in the viral particle or 
damage to the capsid after B-PAC treatment (Fig 4, 4a and b). 
ELISA binding study 
The PGM coating on the plate led to a very high background, without any significant difference 
between the controls and test wells. Further investigation revealed that the primary antibody 
(IgA) bound unspecifically to the PGM resulting in detection even in control wells. Hence, no 
conclusive results were obtained at this time while the screening for additional specific 
antibodies continues to be researched. 
Discussion 
 
As there are an increasing number of studies that examine antiviral properties of natural 
polyphenols, it is equally important to assess them in terms of their antiviral potential, compare 
their effect when these polymeric PAC’s are isolated from different sources and when used as 
individual monomeric units. One of the objectives of this study aimed to compare antiviral 
activities of the monomeric and polymeric units. Overall, the polymeric PAC’s showed a higher 
antiviral effect as compered to monomeric catechins. PAC’s isolated from both blueberries and 
cranberries were observed to have higher effect than commercial procyanidin B2. HAV was 
found to be the most resistant to monomeric treatments amongst the four tested viruses, followed 
by AiV and MNV-1. This provides insights about the structural bioactive units that can be 
beneficial in the design of appropriate preventive anti-viral therapies from natural sources. 
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Extensive research is being carried out to understand the interaction of natural 
polyphenols with the viruses and their host cells. Researchers have proposed several theories as 
to the effects of plant polyphenols in vitro. Berry PACs were reported to have an effect on 
penetration of herpes simplex virus-2 (HSV-2) to the host cells, without much effect on viral 
attachment (23). In another study with HSV-2, PAC from an African resurrection plant was 
found to inhibit both virus attachment and penetration (24). Black raspberry juice was shown to 
be effective in reducing plaque formation of MNV-1 with pre-treatment of host cells that 
prevented binding of the viruses and thus subsequent infection of host cells by treated viruses, 
however post treatment of cells after infection was not shown to have any significant effect 
suggesting that antiviral activity occurred at the point of attachment or entry and not after 
infection or on replication (15).  
In this study, B-PAC was found to prevent viral adsorption to the host cells to a certain 
extent, with lesser effects on viral replication, similar to the results reported by Oh et al., 2012 
with black raspberry juice. These findings are also in agreement with the study conducted with 
permisson extract where no significant effect pre or post infection was reported and that the 
maximal antiviral activity was obtained by direct treatment of the virus particles (25). Similar 
findings were reported for ginsenoside extract (5 μg/mL) treatment against HAV, where a very 
low reduction in titers was reported when the host cells were pre treated with the extract (26).  
In previous studies, similar results with GSE on viral adsorption of FCV-F9, MNV-1, and 
HAV was reported, with less effect on replication (14). However, PAC from blueberry leaves 
was shown to have a pronounced effect on replication of hepatitis C (HCV) (which is an 
enveloped virus) virus by inhibiting expression of NS-3 gene (non-structural gene-3), along with 
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blocking of nuclear ribonucleoprotein essential for subgenomic replication (27). Thus, the 
mechanism of action seems to differ depending on the virus (enveloped versus non-enveloped) 
and the source of PAC.  
Antiviral activity of monomeric and polymeric units for PAC was compared in this study 
in order to understand if a particular subunit had a higher antiviral activity and that which 
component contributes more towards the antiviral effect of B-PAC. FCV-F9 titers were reduced 
to undetectable levels with 1 mg/ml B-PAC after 5 min, whereas with catechin hydrate and 
procyanidin B2, a treatment time of 3 h was needed to exert the same effect. In case of MNV-1, 
1 mg/ml B-PAC reduced titers to undetectable levels within 3 h, however procyanidin B2 at 1 
mg/ml reduced MNV-1 titers by 1.23 log PFU/ml and catechin hydrate to undetectable levels 
only after 24h. Similar observations were reported for HAV with reduction to undetectable levels 
within 3h with 1 mg/ml B-PAC, however no significant change in titers was observed with either 
catechin or procyanidin B2 after 24h. B-PAC at 1 mg/ml reduced AiV titers by 2.45 log PFU/ml 
after 24h, however catechin and procyanidin B2 at 1mg/ml led to a reduction of 0.66 and 0.67 
log PFU/ml after 24h. These comparisons indicate that the individual subunits alone do not 
contribute to the antiviral activity but the PAC in its entirety with its polymeric structure is 
necessary to cause viral reduction. 
With regards to effects on viral structure, in the current study, TEM observations showed 
that the B-PAC treatment had a pronounced effect on the structure of the viral particles where 
visible damage to the outer capsid was seen with disruption of the capsid and release of internal 
contents for FCV-F9, MNV-1 and HAV. The treatment material was also seen to bind to viral 
particles in some fields of observations. Binding of the treatment material to viral particle could 
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block the binding of the virus capsid to the host cell receptors, and prevent host attachment. This 
finding is also consistent with the reduction in the titers observed in the host binding/attachment 
assays. Thus, the B-PAC treatment seems to exert its antiviral activity by destroying the viral 
capsid and blocking the binding receptors, both leading to prevention of host attachment. 
However, no significant damage to the viral capsid by the treatment was observed for Aichi 
virus. 
 With regards to understanding the effect of treatments on viral capsid through ELISA, no 
clear mechanism could be established given the high background, and the non-specific binding 
of the primary antibody to PGM. Thus, further research to screen for specific primary antibodies 
for use and optimization of the ELISA-PGM binding assay is on-going. There are several other 
methods proposed in the literature that can be carried out to distinguish between intact or 
damaged capsid. Intercalating dyes such as propidiummonoazide along with RT-PCRhave been 
used to distinguish between infectious and non-infectious enteric virus (Coxsackievirus, 
poliovirus, echovirus, and Norwalk virus) particles and could distinguish noninfectious or 
inactivated viruses treated at 72°C and 37°C, however, the method could not detect enteroviruses 
that were rendered noninfectious by treatment at 19°C (28). The principle of PGM binding to 
distinguish intact and non-intact capsid could also be tested using a different method of detection 
such as RT-PCR, which could overcome the problem of high background in the control (29).  
 Nonetheless, this data presented in this research provided insights on the 
structural units of polyphenols that have higher antiviral activity, their effects on viral attachment 
to host and replication, and on viral structure by TEM. Overall, gaining insights on the effect of 
individual subunits of the tested polyphenols and their mode of action on the target viruses is 
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essential towards designing future animal feeding studies, clinical trials and potential antiviral 
therapies. 
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Appendix D 
 
Table 4.1 Effect of monomeric catechins and procyanidin B2 on FCV-F9 titers at 37
o
C over 24h 
  Recovered titer (Log PFU/ml) 
Time 
(hour) 
PBS  
(pH 7.2) 
Catechin 
hydrate 
(5 mg/ml) 
Catechin 
hydrate 
(1 mg/ml) 
Procyanidin 
B2 
(1 mg/ml) 
Procyanidin 
B2 
(0.5 mg/ml) 
1 4.71 ± 0.18
A
 0
C
 4.73±0.37
A
 4.04±0.24
 AB
 4.45±0.05
A
 
3 4.71 ± 0.15
A
 0
C
 3.97±0.16
B
 0
C
 0
C
 
6 4.77 ± 0.01
A
 0
C
 0
C
 0
C
 0
C
 
24 4.73 ± 0.04
A
 0
C
 0
C
 0
C
 0
C
 
Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
 
Table 4.2 Effect of monomeric catechins and procyanidin B2 on MNV-1 titers at 37
o
C over 24h 
  Recovered titer (Log PFU/ml) 
Time 
(hour) 
PBS  
(pH 7.2) 
Catechin 
hydrate 
(5 mg/ml) 
Catechin 
hydrate 
(1 mg/ml) 
Procyanidin 
B2 
(1 mg/ml) 
Procyanidin 
B2 
(0.5 mg/ml) 
3 4.80 ± 0.07
 A
 3.04 ± 0.20
 B
 4.38±0.09
 A
 4.55±0.16
 A
 4.65±0.05
 A
 
6 4.41 ± 0.04
 A
 0
 C
 4.63±0.03
 A
 4.67±0.08
 A
 4.49±0.08
 A
 
24 4.64 ± 0.04
 A
 0
 C
 0
 C
 3.41±0.15
 B
 4.43±0.07
 A
 
Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
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Table 4.3 Effect of monomeric catechins and procyanidin B2 on HAV titers at 37
o
C over 24h 
  Recovered titer (Log PFU/ml) 
Time 
(hour) 
PBS  
(pH 7.2) 
Catechin 
hydrate  
(5 mg/ml) 
Catechin 
hydrate  
(1 mg/ml) 
Procyanidin B2 
(1 mg/ml) 
Procyanidin B2 
(0.5 mg/ml) 
3 4.68 ± 0.08
 A
 4.64 ± 0.03
 A
 4.56 ± 0.16
 A
 4.64 ± 0.04
 A
 4.77±0.04
 A
 
6 4.64 ± 0.10
 A
 4.64 ± 0.05
 A
 4.72 ± 0.05
 A
 4.68 ± 0.04
 A
 4.70±0.03
 A
 
24 4.40 ± 0.04
 A
 4.64 ± 0.03
 A
 4.74 ± 0.04
 A
 4.44 ± 0.05
 A
 4.30±0.03
 A
 
Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
 
 
Table 4.4 Effect of monomeric catechins and procyanidin B2 on AiV titers at 37
o
C over 24h 
  Recovered titer (Log PFU/ml) 
Time 
(hour) 
PBS  
(pH 7.2) 
Catechin 
hydrate  
(5 mg/ml) 
Catechin 
hydrate  
(1 mg/ml) 
Procyanidin B2 
(1 mg/ml) 
Procyanidin B2 
(0.5 mg/ml) 
3 4.40 ± 0.06
 A
 4.04 ± 0.26
 A
 3.63 ± 0.04
 B
 3.99±0.27
 A
 4.17±0.02
 A
 
6 4.46 ± 0.03
 A
 3.58 ± 0.03
 B
 3.64 ± 0.02
 B
 3.97±0.16
 A
 4.34±0.06
 A
 
24 4.30 ± 0.22
 A
 3.35 ± 0.18
 B
 3.64 ± 0.03
 B
 3.63±0.03
 B
 4.33±0.05
 A
 
Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml. 
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Table 4.5 Effect of blueberry proanthocyanidins (B-PAC at 0.5mg/ml) on binding of FCV-F9, MNV-1, HAV and AiV at 37
o
C 
 
 Recovered titer/ Reduction (Log PFU/ml) 
Virus 
Control 
(DMEM) 
Blueberry PAC 
(0.5 mg/ml) 
FCV-F9 6.17 ±0.02
A
 0 5.54±0.10
A
         0.63 
MNV-1 5.76±0.07
A
 0 5.22±0.10
A
 0.54 
HAV 5.83±0.02
A
 0 5.49±0.09
A
 0.34 
AiV 4.71±0.04
A
 0 4.09±0.38
A
 0.62 
 
 
 
 
Table 4.6 Effect of blueberry proanthocyanidins (B-PAC at 0.5mg/ml) on replication of FCV-F9, MNV-1, HAV and AiV at 
37
o
C 
 Recovered titer/Reduction (Log PFU/ml) 
Virus 
Control 
(DMEM) 
Blueberry PAC 
(0.5 mg/ml) 
FCV-F9 6.33±0.02
A
 0 5.95±0.03
A
 0.38 
MNV-1 5.72±0.03
A
 0 5.49±0.09
A
 0.23 
HAV 5.73±0.03
A
 0 5.7±0.04
A
 0.03 
AiV 4.73±0.03
A
 0 4.43±0.10
A 
0.30 
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Figure 4.1 TEM images of FCV-F9 (1a), MNV-1 (2a), HAV (3a) and AiV (4a) controls in sterile 
distilled deionized water and FCV-F9 (1b), MNV-1 (2b), HAV (3b) and AiV (4b) treated with 
B-PAC at 0.5 mg/ml for 15min, 1 h, 30 min and 1 h respectively; controls in sterile distilled 
deionized water; and B-PAC background control (5).  
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Figure 4.1 Continued 
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Figure 4.1 Continued 
 
4a 4b 
5 
142 
 
Chapter 5 Conclusion 
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With the rise in the number of foodborne diseases caused by enteric viruses, there is a 
need to develop effective mitigation strategies to control their spread. In the current absence of 
vaccination or effective treatment options for human norovirus infections, natural alternatives are 
being evaluated (141). Plant derived polyphenols and their associated health benefits as 
antimicrobials against bacteria are well established (142-145). Blueberries are known to have a 
broad spectrum of health benefits such as prevention of cardiovascular disorders, age-induced 
oxidative stress, inflammatory responses, and diverse degenerative diseases along with anti-
carcinogenic, neuro-protective, cardio-protective, antibacterial, and antiviral properties (148).  
This study determined that blueberry proanthocyanidins (B-PAC) and commercial 
blueberry juice (BJ) have a significant effect in reducing the titers of human norovirus surrogates 
(FCV-F9 and MNV-1), HAV, and AiV in a dose (for B-PAC) and time-dependent manner. For 
B-PAC to be used as a therapeutic antiviral agent, evaluation of its effectiveness in model food 
systems is important. B-PAC was examined for it antiviral activity in two model food systems, 
namely apple juice and 2% milk. These systems were chosen for their high carbohydrate and 
sugar content (apple juice) and for their high protein and lipid content (milk). Antiviral activity 
of the treatments was enhanced in the presence of apple juice, whereas the activity though 
retained, was at a reduced level in the presence of milk.  
The study of the effects of B-PAC as an antiviral also includes the determination of its 
potential effects after consumption. Effectiveness of B-PAC in the gastrointestinal environment 
when consumed orally as potential treatment options against the above foodborne viruses was 
studied using simulated gastrointestinal fluids (in the absence of available animal models). The 
results showed that B-PAC had a significant effect on viral titers under simulated intestinal 
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conditions. This study also aimed at understanding the possible mode of action of B-PAC and its 
effect on the infectivity and integrity of the tested viral particles through time of addition assays 
and transmission electron microscopy. Results showed moderate effect on the viral particles with 
either damaged viral capsid or binding by PAC, possibly preventing their attachment to host 
cells. 
The overall results from this study provided an understanding of the effective optimum 
concentration levels of B-PAC and time required to reduce the titers of the target viruses, in 
model food systems and under simulated gastrointestinal conditions.  Additionally, insights on 
the mechanism of action were obtained. In future, studies on developing strategies for sustained 
release or encapsulation may be needed. Furthermore, feeding studies using animal models 
(using surrogate viruses for human noroviruses in the current absence of suitable animal models 
or human feeding studies) as well as toxicity studies are necessary. However, recommendations 
for consumption as therapeutic options or health claims should not be made without supporting 
clinical trial data and appropriate regulatory approvals. 
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